var docs;if (!docs) docs =[]; docs["90"]={"9000":"<p><b>Title</b> HMG-CoA Reductase Inhibitors (Statins) / Ciprofibrate</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ciprofibrate may enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of HMG-CoA reductase inhibitors and ciprofibrate if possible. Each have the potential to cause muscle toxicity (including rhabdomyolysis) when used as monotherapy, and use of these agents in combination may increase this risk. The benefits of concomitant therapy should be carefully weighed against the risks. Patients receiving concomitant therapy should be monitored closely for signs/symptoms of muscle toxicity.</p>\n<div>\n <p><b>HMG-CoA Reductase Inhibitors (Statins) Interacting Members</b> AtorvaSTATin, Fluvastatin, Lovastatin, Pitavastatin, Pravastatin, Red Yeast Rice, Rosuvastatin, Simvastatin</p>\n</div> \n<p><b>Discussion</b> Both the HMG-CoA reductase inhibitors and fibrates have been associated with muscle toxicities (including rhabdomyolysis) in monotherapy,<sup>1,2</sup> and the risk may be greater when these agents are used in combination. In a review of published case reports of rhabdomyolysis associated with fibrate therapy, gemfibrozil was associated with the greatest number of events followed by bezafibrate, fenofibrate, ciprofibrate, and clofibrate.<sup>3</sup> Of the 6 cases associated with ciprofibrate, 4 cases were reported in patients receiving concomitant HMG-CoA reductase inhibitors.<br> <br>Ciprofibrate product labeling recommends avoiding concomitant use with HMG-CoA reductase inhibitors.<sup>2</sup> If combined use is considered, the benefits should be carefully weighed against the risks, and if combined, patients should be closely monitored for muscle toxicities.<sup>2</sup><br><br>The mechanism by which concomitant use of ciprofibrate and HMG-CoA reductase inhibitors may lead to myopathy is uncertain. Ciprofibrate is not known to be an inhibitor of any cytochrome P450 enzymes involved in HMG-CoA reductase inhibitor metabolism.<sup>2</sup> The possible increase in muscle toxicity with concomitant therapy may be additive as both agents are known to increase this risk. However, the effect of ciprofibrate on transporters known to affect HMG-CoA reductase inhibitor disposition has not been investigated.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Molokhia M, McKeigue P, Curcin V, Majeed A. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006. <i>PLoS One</i>. 2008;3(6):e2522. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18575628\">[PubMed 18575628]</a></p>\n<p>2. Ciprofibrate [summary of product characteristics]. Harlington Road, Hillingdon, UK: NRIM Limited; November 2014.</p>\n<p>3. Wu J, Song Y, Li H, Chen J. Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. <i>Eur J Clin Pharmacol</i>. 2009;65(12):1169-1174. PubMed 19756555]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9001":"<p><b>Title</b> CycloSPORINE (Systemic) / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ritonavir may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider empiric cyclosporine dose reductions and monitor cyclosporine serum concentrations closely if ritonavir is initiated.</p> \n<p><b>Discussion</b> One case series described the initiation of ritonavir-boosted protease inhibitor therapy in 3 patients receiving cyclosporine as part of an immunosuppressive regimen after liver transplant.<sup>1</sup> Two patients received lopinavir/ritonavir, and one received indinavir/ritonavir (after initially experiencing adverse effects with lopinavir/ritonavir). Addition of protease inhibitor therapy necessitated a 5%-20% decrease in cyclosporine dose in order to maintain therapeutic trough concentrations.<sup>1</sup> Another case series described 2 patients receiving cyclosporine, one who initiated amprenavir/ritonavir and one who initiated fosamprenavir.<sup>2</sup> In the patient who initiated amprenavir/ritonavir, a 12-fold decrease in cyclosporine dose was required to maintain therapeutic concentrations. In the patient who initiated fosamprenavir alone, a 3.5-fold decrease in cyclosporine dose was required, suggesting that the presence of ritonavir may have a greater impact on cyclosporine pharmacokinetics than that of protease inhibitors alone.<sup>2</sup> <br><br>Product labeling for cyclosporine warns that ritonavir may increase cyclosporine concentrations and caution should be used when these agents are coadministered.<sup>3</sup> Ritonavir prescribing information warns that ritonavir is likely to increase cyclosporine concentrations and increased monitoring of cyclosporine serum concentrations should be conducted.<sup>4</sup><br><br>The mechanism of this interaction is inhibition of CYP3A4 and P-glycoprotein by ritonavir, an enzyme and transporter responsible for cyclosporine metabolism and disposition.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vogel M, Voigt E, Michaelis HC, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. <i>Liver Transpl</i>. 2004;10(7):939-944. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15237382\">[PubMed 15237382]</a></p>\n<p>2. Guaraldi G, Cocchi S, Codeluppi M, et al. Pharmacokinetic interaction between amprenavir/ritonavir and fosamprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation. <i>Transplant Proc</i>. 2006;38(4):1138-1140. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16757288\">[PubMed 16757288]</a></p>\n<p>3. <i>Neoral</i> (cyclosporine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceutical Corporation; May 2013. </p>\n<p>4. <i>Norvir</i> (ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; November 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9002":"<p><b>Title</b> Vasodilators (Organic Nitrates) / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the vasodilatory effect of Vasodilators (Organic Nitrates). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased vasodilatory effects (eg, hypotension, flushing, tachycardia) if organic nitrates are combined with alcohol.</p>\n<div>\n <p><b>Vasodilators (Organic Nitrates) Interacting Members</b> Isosorbide Dinitrate, Isosorbide Mononitrate, Nicorandil, Nitroglycerin</p>\n</div> \n<p><b>Discussion</b> According to the prescribing information for several organic nitrate products, the vasodilating effects of nitrates may be additive with those of other vasodilators. Alcohol,<br>in particular, has been found to exhibit additive effects of this variety.<sup>1,2,3,4</sup> Caution and monitoring are recommended.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Isosorbide mononitrate [prescribing information]. Princeton, NJ: Kremers Urban Pharmaceuticals Inc; July 2014.</p>\n<p>2. Nitroglycerin transdermal [prescribing information]. Emigsville, PA: Hercon Laboratories Corporation; July 1997.</p>\n<p>3. <i>Ikorel</i> (nicorandil) [summary of product characteristics]. Guildford, Surrey, UK: Sanofi-Aventis; January 2013.</p>\n<p>4. <i>Isordil Titradose</i> (isosorbide dinitrate) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9003":"<p><b>Title</b> Foscarnet / Loop Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Loop Diuretics may increase the serum concentration of Foscarnet. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> When diuretics are indicated during foscarnet treatment, thiazides are recommended over loop diuretics. If patients receive loop diuretics during foscarnet treatment, monitor closely for evidence of foscarnet toxicity.</p>\n<div>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide, Torsemide</p>\n</div> \n<p><b>Discussion</b> Foscarnet US prescribing information warns that loop diuretics may impair foscarnet elimination via inhibition of renal tubular secretion, potentially leading to toxicity.<sup>1</sup> When possible, a thiazide diuretic is recommended as a substitute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Foscavir</i> (foscarnet) [prescribing information]. Lake Forest, IL: Hospira Inc; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9004":"<p><b>Title</b> Aminoglycosides / Foscarnet</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Foscarnet may enhance the nephrotoxic effect of Aminoglycosides. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of foscarnet and aminoglycoside antibiotics, unless the expected benefits of combined treatment outweigh the risks.</p>\n<div>\n <p><b>Aminoglycosides Interacting Members</b> Amikacin, Arbekacin, Gentamicin (Systemic), Isepamicin, Kanamycin, Neomycin, Streptomycin, Tobramycin (Systemic)</p>\n</div> \n<p><b>Discussion</b> Foscarnet US prescribing information recommends avoiding its use in combination with several other nephrotoxic agents (specifically, acyclovir, aminoglycosides, amphotericin B, cyclosporine, methotrexate, tacrolimus, and intravenous pentamidine) due to the potential for additive or synergistic nephrotoxic effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Foscavir</i> (foscarnet) [prescribing information]. Lake Forest, IL: Hospira Inc; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9005":"<p><b>Title</b> Amphotericin B / Foscarnet</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Foscarnet may enhance the nephrotoxic effect of Amphotericin B. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of foscarnet and amphotericin B, unless the expected benefits of combined treatment outweigh the risks.</p>\n<div>\n <p><b>Amphotericin B Interacting Members</b> Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex</p>\n</div> \n<p><b>Discussion</b> Foscarnet US prescribing information recommends avoiding its use in combination with several other nephrotoxic agents (specifically, acyclovir, aminoglycosides, amphotericin B, cyclosporine, methotrexate, tacrolimus, and intravenous pentamidine) due to the potential for additive or synergistic nephrotoxic effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Foscavir</i> (foscarnet) [prescribing information]. Lake Forest, IL: Hospira Inc; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9006":"<p><b>Title</b> Acyclovir-Valacyclovir / Foscarnet</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Foscarnet may enhance the nephrotoxic effect of Acyclovir-Valacyclovir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of foscarnet and acyclovir or valacyclovir, unless the expected benefits of combined treatment outweigh the risks.</p>\n<div>\n <p><b>Acyclovir-Valacyclovir Interacting Members</b> Acyclovir (Systemic), ValACYclovir</p>\n</div> \n<p><b>Discussion</b> Foscarnet US prescribing information recommends avoiding its use in combination with several other nephrotoxic agents (specifically, acyclovir, aminoglycosides, amphotericin B, cyclosporine, methotrexate, tacrolimus, and intravenous pentamidine) due to the potential for additive or synergistic nephrotoxic effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Foscavir</i> (foscarnet) [prescribing information]. Lake Forest, IL: Hospira Inc; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9007":"<p><b>Title</b> Methotrexate / Foscarnet</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Foscarnet may enhance the nephrotoxic effect of Methotrexate. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of foscarnet and methotrexate, unless the expected benefits of combined treatment outweigh the risks.</p> \n<p><b>Discussion</b> Foscarnet US prescribing information recommends avoiding its use in combination with several other nephrotoxic agents (specifically, acyclovir, aminoglycosides, amphotericin B, cyclosporine, methotrexate, tacrolimus, and intravenous pentamidine) due to the potential for additive or synergistic nephrotoxic effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Foscavir</i> (foscarnet) [prescribing information]. Lake Forest, IL: Hospira Inc; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9008":"<p><b>Title</b> Tacrolimus (Systemic) / Foscarnet</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Foscarnet may enhance the nephrotoxic effect of Tacrolimus (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of foscarnet and systemic tacrolimus, unless the expected benefits of combined treatment outweigh the risks.</p> \n<p><b>Discussion</b> Foscarnet US prescribing information recommends avoiding its use in combination with several other nephrotoxic agents (specifically, acyclovir, aminoglycosides, amphotericin B, cyclosporine, methotrexate, tacrolimus, and intravenous pentamidine) due to the potential for additive or synergistic nephrotoxic effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Foscavir</i> (foscarnet) [prescribing information]. Lake Forest, IL: Hospira Inc; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9009":"<p><b>Title</b> CycloSPORINE (Systemic) / Foscarnet</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Foscarnet may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of foscarnet and systemic cyclosporine, unless the expected benefits of combined treatment outweigh the risks.</p> \n<p><b>Discussion</b> Foscarnet US prescribing information recommends avoiding its use in combination with several other nephrotoxic agents (specifically, acyclovir, aminoglycosides, amphotericin B, cyclosporine, methotrexate, tacrolimus, and intravenous pentamidine) due to the potential for additive or synergistic nephrotoxic effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Foscavir</i> (foscarnet) [prescribing information]. Lake Forest, IL: Hospira Inc; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9010":"<p><b>Title</b> Zoledronic Acid / Calcitonin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Calcitonin may enhance the hypocalcemic effect of Zoledronic Acid. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of hypocalcemia (serum calcium, signs/symptoms of hypocalcemia) when using calcitonin and zoledronic acid in combination. The risk may be greater with the Zometa brand of zoledronic acid, which may require more frequent administration than the Reclast brand of zoledronic acid.</p> \n<p><b>Discussion</b> The prescribing information for the Zometa brand of zoledronic acid cautions that concurrent use of zoledronic acid and calcitonin may result in additive calcium-lowering effects resulting in a greater risk for hypocalcemia.<sup>1,2</sup> Both zoledronic acid and calcitonin have been independently associated with clinically meaningful hypocalcemia, and both products call for close monitoring of serum calcium and appropriate use of calcium and vitamin D supplementation in order to prevent hypocalcemia.<sup>1,2,3,4</sup><br><br>The Reclast brand of zoledronic acid does not contain this specific warning,<sup>4</sup> and while the risks associated with such a combination may be lower due to the generally lower cumulative doses of zoledronic used (since generally administered between once every 1 to 2 years), such use of zoledronic acid still carries a risk for hypocalcemia.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zometa</i> (zoledronic acid) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2015.</p>\n<p>2. <i>Zometa</i> (zoledronic acid) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc.; December 2014.</p>\n<p>3. <i>Miacalcin</i> (calcitonin-salmon) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2009.</p>\n<p>4. <i>Reclast</i> (zoledronic acid) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9011":"<p><b>Title</b> Heparin / Telavancin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This contraindication applies only to intravenous (IV) unfractionated heparin. The use of subcutaneous heparin is not impacted by this labeled contraindication.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Telavancin may diminish the therapeutic effect of Heparin. Specifically, telavancin may artificially increase the results of laboratory tests commonly used to monitor IV heparin effectiveness, which could lead to incorrect decisions to decrease heparin doses. <b>Severity</b> Major <b>Onset</b> Immediate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Concurrent use of telavancin with intravenous unfractionated heparin is contraindicated. The concern is that telavancin interferes with laboratory monitoring of heparin effects for up to 18 hours after telavancin administration. Use of subcutaneous heparin, which does not rely on monitoring of the activated partial thromboplastin time (aPTT), is not impacted by this contraindication.</p> \n<p><b>Discussion</b> Concurrent use of telavancin with intravenous (IV) unfractionated heparin (UFH) is contraindicated according to the telavancin prescribing information.<sup>1</sup> Telavancin can bind to artificial phospholipids found in coagulation reagents, reducing the in vitro clotting process and resulting in artificially prolonged clotting times. In the presence of telavancin, the activated partial thromboplastin time (aPTT) demonstrated concentration-dependent increases in clotting times.<sup>2,3</sup> For aPTT in particular, reagents demonstrated a dose-dependent effect to telavancin with all reagents displaying more than a 10% increase in value compared with pooled plasma results.<sup>2</sup> No effect of telavancin was seen in non-phospholipid dependent assays such as chromogenic anti-factor Xa assay, functional factor X activity assay, fibrinogen, thrombin time, and D-dimer testing.<sup>1,2</sup><br><br>As telavancin can falsely elevate aPTT, incorrect interpretation of such test results may lead to suboptimal anticoagulation and harmful clinical outcomes. This testing interaction appears to be completely responsible for the listed contraindication since telavancin does not appear associated with either an increased risk for bleeding or hypercoagulability.<sup>1</sup> Subcutaneous heparin does not require aPTT monitoring, so telavancin can be used in patients using subcutaneous heparin. If testing of heparin effects is necessary during concurrent telavancin, aPTT monitoring should be conducted immediately prior to the next telavancin dose (i.e., as long after the telavancin dose as possible) and/or use of a non-phospholipid dependent test should be considered.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Vibativ</i> (telavancin) [prescribing information]. South San Francisco, CA: Theravance Biopharma US, Inc.; November 2014.</p>\n<p>2. Gosselin R, Dager W, Roberts A, et al. Effect of telavancin (Vibativ) on routine coagulation test results. <i>Am J Clin Pathol</i>. 2011;136(6):848-854. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22095369\">[PubMed 22095369]</a></p>\n<p>3. Barriere SL, Goldberg MR, Janc JW, Higgins DL, Macy PA, Adcock DM. Effects of telavancin on coagulation test results. <i>Int J Clin Pract</i>. 2011;65(7):784-789. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21564449\">[PubMed 21564449]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9015":"<p><b>Title</b> Acenocoumarol / Amorolfine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Amorolfine may enhance the anticoagulant effect of Acenocoumarol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor INR in acenocoumarol-treated patients more closely in the first several weeks following initiation of amorolfine.</p> \n<p><b>Discussion</b> Two published case reports describe women aged 60 and 71 years receiving long-term anticoagulation with acenocoumarol whose INR increased to 5.7 to 7.7 (from a baseline of approximately 3) following only 1 to 2 applications of amorolfine nail lacquer (5%, applied every 2 weeks).<sup>1</sup> The mechanism of this possible interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Morales-Molina JA, Fayet-Perez A, Martinez-Plata E, Perez-Moyano R, Molina-Arrebola MA. Interaction between amorolfine and acenocoumarol. <i>Eur J Clin Pharmacol</i>. 2012;68(12):1687-1688. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22648278\">[PubMed 22648278]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9016":"<p><b>Title</b> Levodopa / Isoniazid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Isoniazid may diminish the therapeutic effect of Levodopa. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for reduced levodopa effectiveness and worsening of Parkinson disease symptoms if combined with isoniazid.</p> \n<p><b>Discussion</b> In a clinical study, Parkinson disease (PD) symptoms were assessed in 20 patients on stable doses of levodopa and a dopa decarboxylase inhibitor (eg, carbidopa) before and after treatment with isoniazid (150 mg three times daily) for 5 weeks.<sup>1</sup> During isoniazid therapy, “off” time (when symptoms are inadequately controlled) increased 92% and an increase in motor disability was also reported. Due to its negative effects on mobility, isoniazid was withdrawn in all patients and a return to baseline PD control was achieved.<sup>1</sup> In support of this clinical study, a few case reports describe the worsening of PD symptoms when isoniazid was added to patients stabilized on levodopa therapy.<sup>2,3</sup> In one case, PD symptoms improved after discontinuation of isoniazid, only to worsen again with rechallenge.<sup>2</sup> In another case, symptoms improved with increased doses of levodopa and cabergoline.<sup>3</sup><br><br>Prescribing information for levodopa-containing products warns that isoniazid may reduce the effectiveness of levodopa and patients should be monitored for worsening PD symptoms.<sup>4,5,6</sup> <br><br>The mechanism of this potential interaction has not been fully investigated, but isoniazid may inhibit dopa decarboxylase.<sup>1,2</sup> Unlike peripherally acting dopa decarboxylase inhibitors that are intentionally given with levodopa to improve its delivery to the central nervous system (eg, carbidopa, benserazide), isoniazid is able to penetrate the blood-brain barrier.<sup>7</sup> The inhibition of dopa decarboxylase in the central nervous system by isoniazid would prevent the conversion of levodopa to dopamine and reduce its efficacy.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Gershanik OS, Luguin MR, Scipioni O, Obeso JA. Isoniazid therapy in Parkinson's disease. <i>Mov Disord</i>. 1988;3(2):133-139. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3221901\">[PubMed 3221901]</a></p>\n<p>2. Wenning GK, O'Connell MT, Patsalos PN, Quinn NP. A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease. <i>Mov Disord</i>. 1995;10(5):664-667. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8552121\">[PubMed 8552121]</a></p>\n<p>3. Ohki M, Tayama N. Dysphagia due to isoniazid therapy for tuberculosis in a patient with Lewy body dementia. <i>Auris Nasus Larynx</i>. 2010;40(3):327-329. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22608343\">[PubMed 22608343]</a></p>\n<p>4. <i>Duopa</i> (carbidopa and levodopa) [prescribing information]. North Chicago, IL: AbbVie Inc; January 2015.</p>\n<p>5. <i>Stalevo</i> (carbidopa, levodopa, and entacapone) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2014.</p>\n<p>6. <i>Sinemet</i> (carbidopa and levodopa) [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; July 2014.</p>\n<p>7. Isoniazid [prescribing information]. Pomona, NY: Barr Laboratories Inc; August 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9017":"<p><b>Title</b> Pranlukast / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pranlukast. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Monitor patients receiving this combination closely for evidence of pranlukast adverse effects.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The pranlukast labeling cautions that CYP3A4 inhibitors may increase pranlukast concentrations,<sup>1</sup> possibly increasing the risk of adverse effects. Labeling cites data from a study in cynomolgus monkeys showing a 2-fold increase in pranlukast AUC and a 2.8-fold increase in pranlukast maximum serum concentration (Cmax) with concurrent use of the strong CYP3A4 inhibitor ketoconazole.<sup>1</sup><br><br>In contrast, the pranlukast AUC and Cmax were increased by only an average of 6% and 17%, respectively, with concurrent use of the strong CYP3A4 inhibitor clarithromycin (200 mg twice/day for 7 days) in a study of 15 healthy volunteers.<sup>2</sup> An in vitro study using human liver microsomes also concluded that clarithromycin and erythromycin had little impact on pranlukast metabolism and that both ketoconazole and an anti-CYP3A4 antibody were each capable of inhibiting pranlukast metabolism by 44% to 56%.<sup>3</sup><br><br>These somewhat conflicting findings call into question the clinical importance of this possible interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Onon</i> (pranlukast) [Japan Pharmaceutical Reference]. Osaka, Japan: Ono Pharmaceutical Co., Ltd.; March 2010.</p>\n<p>2. Nakade S, Yamauchi A, Komaba J, et al. Effect of clarithromycin on the pharmacokinetics of pranlukast in healthy volunteers. <i>Drug Metab Pharmacokinet</i>. 2008;23(6):428-433. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19122337\">[PubMed 19122337]</a></p>\n<p>3. Yoneda K, Matsumoto I, Sutoh F, et al. In vitro metabolism and inhibitory effects of pranlukast in human liver microsomes. <i>Biol Pharm Bull</i>. 2009;32(4):688-693. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19336906\">[PubMed 19336906]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9018":"<p><b>Title</b> CYP3A4 Substrates (High risk with Inhibitors) / Pranlukast</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Pranlukast may increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>CYP3A4 Substrates (High risk with Inhibitors) Interacting Members</b> Abemaciclib, Acalabrutinib, Ado-Trastuzumab Emtansine, Alfentanil, Alfuzosin, Alitretinoin (Systemic), ALPRAZolam, Amiodarone, AmLODIPine, Aprepitant, ARIPiprazole, ARIPiprazole Lauroxil, Asunaprevir, Atazanavir, AtorvaSTATin, Avanafil, Axitinib, Barnidipine, Benidipine, Benzhydrocodone, Blonanserin, Bosutinib, Brexpiprazole, Brigatinib, Bromocriptine, Bromperidol, Budesonide (Systemic), Buprenorphine, BusPIRone, Cabazitaxel, Cabozantinib, Calcitriol (Systemic), CarBAMazepine, Cariprazine, Ceritinib, ChlordiazePOXIDE, Chloroquine, Cilnidipine, Cilostazol, Cinacalcet, Cisapride, Citalopram, Clarithromycin, ClonazePAM, Cobimetinib, Colchicine, Conivaptan, Copanlisib, Crizotinib, CycloSPORINE (Systemic), Cyproterone, Dabrafenib, Daclatasvir, Dapoxetine, Darifenacin, Darunavir, Dasatinib, Deflazacort, Dexamethasone (Systemic), DiazePAM, Digitoxin, Dihydroergotamine, DilTIAZem, Disopyramide, DOCEtaxel, Domperidone, Doxazosin, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Dronedarone, Dydrogesterone, Ebastine, Elbasvir, Eletriptan, Eliglustat, Eplerenone, Ergoloid Mesylates, Ergonovine, Ergotamine, Erlotinib, Erythromycin (Systemic), Escitalopram, Eszopiclone, Ethosuximide, Etizolam, Everolimus, Felbamate, Felodipine, FentaNYL, Fesoterodine, Flibanserin, Flurazepam, Fluticasone (Oral Inhalation), Fosaprepitant, Gefitinib, Grazoprevir, GuanFACINE, Halofantrine, Haloperidol, HYDROcodone, HYDROXYprogesterone Caproate, Ibrutinib, Irinotecan (Conventional), Irinotecan (Liposomal), Isavuconazonium Sulfate, Isosorbide Dinitrate, Isosorbide Mononitrate, Isradipine, Itraconazole, Ivabradine, Ivacaftor, Ixabepilone, Ketamine, Lacidipine, Lapatinib, Lercanidipine, Levomilnacipran, Lidocaine (Systemic), Lidocaine (Topical), Lomitapide, Lovastatin, Lurasidone, Macitentan, Manidipine, Maraviroc, Mefloquine, Methadone, Methylergonovine, Midazolam, Midostaurin, MiFEPRIStone, Mirodenafil, Mirtazapine, Naloxegol, Nefazodone, Neratinib, NiCARdipine, NIFEdipine, Nilotinib, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Olaparib, Olmutinib, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, OxyCODONE, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pimavanserin, Pimozide, Piperaquine, Praziquantel, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ranolazine, Reboxetine, Regorafenib, Ribociclib, Rupatadine, Ruxolitinib, Salmeterol, SAXagliptin, Sildenafil, Silodosin, Simeprevir, Simvastatin, Sirolimus, Solifenacin, Sonidegib, Stiripentol, SUFentanil, SUNItinib, Suvorexant, Tacrolimus (Systemic), Tadalafil, Tamoxifen, Tamsulosin, Telaprevir, Telithromycin, Temsirolimus, Teniposide, Tezacaftor, TiaGABine, Tofacitinib, Tolterodine, Tolvaptan, Trabectedin, TraZODone, Triazolam, Trimipramine, Udenafil, Valbenazine, Vardenafil, Vemurafenib, Venetoclax, Venlafaxine, Verapamil, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vinflunine, Vinorelbine, Zopiclone</p>\n</div> \n<p><b>Discussion</b> The pranlukast labeling cautions that pranlukast, which is a CYP3A4 substrate, may competitively inhibit the metabolism of other CYP3A4 substrates, potentially increasing their concentrations and effects.<sup>1</sup><br><br>Specific data in support of this warning are lacking. According to a study in 15 healthy volunteers, the AUC of the CYP3A4 substrate clarithromycin was increased by only an average of 13% with concurrent pranlukast (single dose of 225 mg given on day 7 of clarithromycin, and compared to AUC from day 5).<sup>2</sup> Data from two separate in vitro studies similarly concluded that pranlukast demonstrated no substantial impact on CYP3A4-mediated metabolism.<sup>3,4</sup><br><br>These somewhat conflicting findings suggest that clinically important CYP3A4 inhibition by pranlukast is unlikely.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Onon</i> (pranlukast) [Japan Pharmaceutical Reference]. Osaka, Japan: Ono Pharmaceutical Co., Ltd.; March 2010.</p>\n<p>2. Nakade S, Yamauchi A, Komaba J, et al. Effect of clarithromycin on the pharmacokinetics of pranlukast in healthy volunteers. <i>Drug Metab Pharmacokinet</i>. 2008;23(6):428-433. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19122337\">[PubMed 19122337]</a></p>\n<p>3. Yoneda K, Matsumoto I, Sutoh F, et al. In vitro metabolism and inhibitory effects of pranlukast in human liver microsomes. <i>Biol Pharm Bull</i>. 2009;32(4):688-693. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19336906\">[PubMed 19336906]</a></p>\n<p>4. Liu KH, Lee YM, Shon JH, et al. Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. <i>Xenobiotica</i>. 2004;34(5):429-438. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15370959\">[PubMed 15370959]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9019":"<p><b>Title</b> Levodopa / Papaverine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Papaverine may enhance the hypotensive effect of Levodopa. Papaverine may diminish the therapeutic effect of Levodopa. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for reduced levodopa effectiveness and worsening Parkinson disease symptoms if combined with papaverine. Monitor for symptomatic postural hypotension when using this combination.</p> \n<p><b>Discussion</b> A case report describes a 71-year-old patient maintained on levodopa for several years, who experienced a gradual deterioration of her Parkinson condition over several weeks after taking papaverine 100 mg daily.<sup>1</sup> Within one week of papaverine discontinuation, the patient's response to levodopa was restored to its previous level. Six other case reports describe a similar reduction in levodopa effectiveness with the addition of papaverine.<sup>1,2</sup><br><br>Prescribing information for levodopa-containing products warns that because papaverine may reduce the effectiveness of levodopa, patients should be monitored for worsening Parkinson symptoms.<sup>3,4,5</sup> Prescribing information also warns that the combination of levodopa and drugs that may lower blood pressure (ie, papaverine) could result in symptomatic postural hypotension. Although no hypotension was reported in the published cases, increased monitoring is still recommended.<sup>3,4,5</sup><br><br>The mechanism by which papaverine may reduce levodopa effects has not been investigated, but some animal data suggest that papaverine may affect dopamine release and/or metabolism.<sup>6,7</sup> The hypotensive effect of levodopa is not fully understood, but proposed mechanisms include impaired catecholamine action, abnormalities of renin and aldosterone action, and negative inotropic mechanisms leading to decreased cardiac output.<sup>8,9</sup> Combination with agents that also reduce blood pressure may result in an additive hypotensive effect.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Duvoisin RC. Antagonism of levodopa by papaverine. <i>JAMA</i>. 1975;231(8):845-846. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1172755\">[PubMed 1172755]</a></p>\n<p>2. Posner DM. Letter: antagonism of levodopa by papaverine. <i>JAMA</i>. 1975;233(7):768. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1173866\">[PubMed 1173866]</a></p>\n<p>3. <i>Duopa</i> (carbidopa and levodopa) [prescribing information]. North Chicago, IL: AbbVie Inc; January 2015.</p>\n<p>4. <i>Stalevo</i> (carbidopa, levodopa, and entacapone) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2014.</p>\n<p>5. <i>Sinemet</i> (carbidopa and levodopa) [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; July 2014.</p>\n<p>6. Eitan A, Hershkowitz M. The effects of dibutyryl cyclic AMP, theophylline and papaverine on the release of 3H-catecholamines from rat brain striatal and cortical synaptosomes. <i>Eur J Pharmacol</i>. 1977;46(4):323-327. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=201472\">[PubMed 201472]</a></p>\n<p>7. Cubeddu L, Hoffmann IS, Paris VB. Effects of papaverine on the release and metabolism of dopamine in rat striatum. <i>J Pharmacol Exp Ther</i>. 1979;209(1):73-78. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=85703\">[PubMed 85703]</a></p>\n<p>8. Chokroverty S, Barron KD, Katz FH, Del Greco F, Sharp JT. The syndrome of primary orthostatic hypotension. <i>Brain</i>. 1969;92(4):743-768. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5364007\">[PubMed 5364007]</a></p>\n<p>9. Noack C, Schroeder C, Heusser K, Lipp A. Cardiovascular effects of levodopa in Parkinson's disease. <i>Parkinsonism Relat Disord</i>. 2014;20(8):815-818. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24819390\">[PubMed 24819390]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9020":"<p><b>Title</b> Terfenadine / Posaconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Posaconazole may increase the serum concentration of Terfenadine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of posaconazole with terfenadine should be avoided. The combination is contraindicated in Canadian labeling. US labeling does not describe this combination specifically, but the use of posaconazole with CYP3A4 substrates that are known to prolong the QTc interval (eg, astemizole, terfenadine) is contraindicated. Concomitant use is expected to substantially increase the risk for QTc prolongation and/or the development of torsades de pointes.</p> \n<p><b>Discussion</b> The use of posaconazole with terfenadine is contraindicated in Canadian labeling due to the risk for serious and life-threatening reactions such as QTc prolongation and cardiac arrhythmias (torsades de pointes).<sup>1</sup> US labeling does not describe this combination specifically, but the use of posaconazole with CYP3A4 substrates that are known to prolong the QTc interval is contraindicated.<sup>2</sup> <br><br>Although there are no specific data on the mechanism of this interaction, it is likely due to the ability of posaconazole to inhibit CYP3A4, an enzyme responsible for terfenadine metabolism.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Posanol</i> (posaconazole) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; October 2014</p>\n<p>2. <i>Noxafil</i> (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; June 2012.</p>\n<p>3. Yun CH, Okerholm RA, Guengerich FP. Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. <i>Drug Metab Dispos</i>. 1993;21(3):403-409. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8100494\">[PubMed 8100494]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9021":"<p><b>Title</b> Astemizole / Posaconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Posaconazole may increase the serum concentration of Astemizole. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of posaconazole with astemizole should be avoided. The combination is contraindicated in Canadian labeling. US labeling does not describe this combination specifically, but the use of posaconazole with CYP3A4 substrates that are known to prolong the QTc interval (eg, astemizole, terfenadine) is contraindicated. Concomitant use is expected to substantially increase the risk for QTc prolongation and/or the development of torsades de pointes.</p> \n<p><b>Discussion</b> The use of posaconazole with astemizole is contraindicated in Canadian labeling due to the risk for serious and life-threatening reactions such as QTc prolongation and cardiac arrhythmias (torsades de pointes).<sup>1</sup> US labeling does not describe this combination specifically, but the use of posaconazole with CYP3A4 substrates that are known to prolong the QTc interval is contraindicated.<sup>2</sup> <br><br>Although there are no specific data on the mechanism of this interaction, it is likely due to the ability of posaconazole to inhibit CYP3A4, an enzyme responsible for astemizole metabolism.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Posanol</i> (posaconazole) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; October 2014</p>\n<p>2. <i>Noxafil</i> (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; June 2012.</p>\n<p>3. Matsumoto S, Yamazoe Y. Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine.<i>Br J Clin Pharmacol</i>. 2001;51(2):133-142. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11259984\">[PubMed 11259984]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9022":"<p><b>Title</b> Levodropropizine / CNS Depressants</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CNS Depressants may enhance the CNS depressant effect of Levodropropizine. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> For the majority of patients, no action is required. In individuals who are particularly sensitive to the sedating effects of medications (eg, the elderly), monitor for increased sedation and/or CNS depression if levodropropizine is combined with a CNS depressant.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> International product labeling for levodropropizine warns that increased sedation might occur if levodropropizine is combined with other sedatives, particularly in sensitive individuals (eg, the elderly).<sup>1,2,3</sup><br><br>In contrast to this warning, product labeling in Switzerland describes animal data in which the use of levodropropizine did not potentiate the CNS depressant effects of benzodiazepines, alcohol, phenytoin, or imipramine.<sup>3</sup> Additionally, a study conducted in humans reported that the combination of levodropropizine and benzodiazepines did not change the EEG-pattern compared to benzodiazepine use alone.<sup>3</sup> The stereospecific levodropropizine has also been shown to have significantly fewer CNS depressant effects than the racemic compound dropropizine.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Levotuss</i> (levodropropizine) [summary of product characteristics]. Barcelona, Spain: Rottapharm SL; December 2013. </p>\n<p>2. <i>Zyplo</i> (levodropropizine) [summary of product characteristics]. Rio de Janeiro, Brazil: Bago Laboratories of Brazil SA; June 2014.</p>\n<p>3. <i>Levopront</i> (levodropropizine) [summary of product characteristics]. Lugano, Switzerland: Novintethical; January 2014.</p>\n<p>4. Gatti G, Barzaghi N, Dominijanni R, Cordaro C, Perucca E. Enantioselective effects of levodropropizine and dropropizine on psychomotor functions in normal volunteers: a placebo-controlled, double-blind comparative study. <i>Drugs Exp Clin Res</i>. 1993;19(1):33-39. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8223138\">[PubMed 8223138]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9023":"<p><b>Title</b> Astemizole / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Astemizole. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of astemizole with strong CYP3A4 inhibitors. Product labeling for several inhibitors lists use with astemizole as contraindicated.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> US and Canadian product labeling for several strong CYP3A4 inhibitors recommends against combining these agents with astemizole, either specifically listing astemizole as an agent to avoid or implying this (eg, by recommending against use with QT-prolonging CYP3A4 substrates).<sup>1,2,3,4,5,6,7,8,9,10,11</sup> Labeling for several agents lists such use as contraindicated. Two published in vitro studies support a potential for CYP3A4 inhibitors to increase exposure to astemizole,<sup>12,13</sup> and published case reports support a potential for combined use to cause excessive QT interval prolongation and torsades de pointes.<sup>14,15</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Biaxin</i> (clarithromycin) [prescribing information]. North Chicago, IL: Abbott Laboratories; January 2015.</p>\n<p>2. <i>Victrelis</i> (boceprevir) [product monograph]. Kirkland, QC, Canada: Merck Canada Inc; January 2013.</p>\n<p>3. Ketoconazole [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; January 2012.</p>\n<p>4. <i>Posanol</i> (posaconazole) [product monograph]. Kirkland, QC, Canada: Merck Canada Inc; October 2014.</p>\n<p>5. <i>Noxafil</i> (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; June 2012.</p>\n<p>6. <i>Vfend</i> (voriconazole) [prescribing information]. New York, NY: Pfizer Inc; November 2011.</p>\n<p>7. <i>Vfend</i> (voriconazole) [product monograph]. Kirkland, QC, Canada: Pfizer Canada Inc; February 2013.</p>\n<p>8. <i>Prezista</i> (darunavir) [product monograph]. Toronto, ON, Canada: Janssen Inc; September 2014</p>\n<p>9. <i>Prezcobix</i> (darunavir/cobicistat) [product monograph]. Toronto, ON, Canada: Janssen Inc; June 2014.</p>\n<p>10. <i>Prezista</i> (darunavir) [prescribing information]. Titusville, NJ: Janssen Therapeutics; April 2014.</p>\n<p>11. <i>Holkira Pak</i> (ombitasvir, paritaprevir, ritonavir, dasabuvir) [product monograph]. St-Laurent, QC, Canada: AbbVie Corporation, December 2014.</p>\n<p>12. Matsumoto S, Yamazoe Y. Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine. <i>Br J Clin Pharmacol</i>. 2001;51(2):133-142. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11259984\">[PubMed 11259984]</a></p>\n<p>13. Matsumoto S, Hirama T, Kim HJ, Nagata K, Yamazoe Y. In vitro inhibition of human small intestinal and liver microsomal astemizole O-demethylation: different contribution of CYP2J2 in the small intestine and liver. <i>Xenobiotica</i>. 2003;33(6):615-623. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12851038\">[PubMed 12851038]</a></p>\n<p>14. Tsai WC, Tsai LM, Chen JH. Combined use of astemizole and ketoconazole resulting in torsade de pointes. <i>J Formos Med Assoc</i>. 1997; 96(2):144-146. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9071844\">[PubMed 9071844]</a></p>\n<p>15. Kulkarni SM, Agarwal HK, Shaikh AA. Torsade de pointes complicating treatment with astemizol. <i>Indian Heart J</i>. 1994;46(3):179-180. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7821942\">[PubMed 7821942]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9024":"<p><b>Title</b> Terfenadine / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Terfenadine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of terfenadine with strong CYP3A4 inhibitors. Product labeling for several inhibitors lists use with terfenadine as contraindicated.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> US and Canadian product labeling for several strong CYP3A4 inhibitors recommends against combining these agents with terfenadine, either specifically listing terfenadine as an agent to avoid or implying this (eg, recommending against use with QT-prolonging CYP3A4 substrates).<sup>1,2,3,4,5,6,7,8,9,10,11</sup> Labeling for several agents lists such use as contraindicated. Numerous studies and case reports support a potential for CYP3A4 inhibitors to increase exposure to terfenadine and its active metabolite, and to cause both excessive QT interval prolongation and potentially fatal cardiac arrhythmias.<sup>1,12,13,14,15,16,17,18,19,20,21</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Biaxin</i> (clarithromycin) [prescribing information]. North Chicago, IL: Abbott Laboratories; January 2015.</p>\n<p>2. <i>Victrelis</i> (boceprevir) [product monograph]. Kirkland, QC, Canada: Merck Canada Inc; January 2013.</p>\n<p>3. Ketoconazole [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; January 2012.</p>\n<p>4. <i>Posanol</i> (posaconazole) [product monograph]. Kirkland, QC, Canada: Merck Canada Inc; October 2014.</p>\n<p>5. <i>Noxafil</i> (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; June 2012.</p>\n<p>6. <i>Vfend</i> (voriconazole) [prescribing information]. New York, NY: Pfizer Inc; November 2011.</p>\n<p>7. <i>Vfend</i> (voriconazole) [product monograph]. Kirkland, QC, Canada: Pfizer Canada Inc; February 2013.</p>\n<p>8. <i>Prezista</i> (darunavir) [product monograph]. Toronto, ON, Canada: Janssen Inc; September 2014</p>\n<p>9. <i>Prezcobix</i> (darunavir/cobicistat) [product monograph]. Toronto, ON, Canada: Janssen Inc; June 2014.</p>\n<p>10. <i>Prezista</i> (darunavir) [prescribing information]. Titusville, NJ: Janssen Therapeutics; April 2014.</p>\n<p>11. <i>Holkira Pak</i> (ombitasvir, paritaprevir, ritonavir, dasabuvir) [product monograph]. St-Laurent, QC, Canada: AbbVie Corporation, December 2014.</p>\n<p>12. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI. In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. <i>J Clin Pharmacol</i>. 1994;34(12):1222-1227. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7738219\">[PubMed 7738219]</a></p>\n<p>13. Rodrigues AD, Mulford DJ, Lee RD, et al. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices. <i>Drug Metab Dispos</i>. 1995;23(7):765-775. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7587966\">[PubMed 7587966]</a></p>\n<p>14. Ling KH, Leeson GA, Burmaster SD, Hook RH, Reith MK, Cheng LK. Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes. <i>Drug Metab Dispos</i>. 1995;23(6):631-636. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7587944\">[PubMed 7587944]</a></p>\n<p>15. Jurima-Romet M, Crawford K, Cyr T, Inaba T. Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. <i>Drug Metab Dispos</i>. 1994;22(6):849-857. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7895601\">[PubMed 7895601]</a></p>\n<p>16. Raeissi SD, Hidalgo IJ, Segura-Aguilar J, Artursson P. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers. <i>Pharm Res</i>. 1999;16(5):625-632. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10350002\">[PubMed 10350002]</a></p>\n<p>17. Kim RB, Wandel C, Leake B, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. <i>Pharm Res</i>. 1999;16(3):408-414. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10213372\">[PubMed 10213372]</a></p>\n<p>18. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. <i>JAMA</i>. 1993;269(12):1513-1518. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8445813\">[PubMed 8445813]</a></p>\n<p>19. Mathews DR, McNutt B, Okerholm R, Flicker M, McBride G. Torsades de pointes occurring in association with terfenadine use. <i>JAMA</i>. 1991;266(17):2375-2376. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1920744\">[PubMed 1920744]</a></p>\n<p>20. Zimmermann M, Duruz H, Guinand O, et al. Torsades de Pointes after treatment with terfenadine and ketoconazole. <i>Eur Heart J</i>. 1992;13(7):1002-1003. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1644069\">[PubMed 1644069]</a></p>\n<p>21. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr. Torsades de pointes occurring in association with terfenadine use. <i>JAMA</i>, 1990;264(21):2788-2790. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1977935\">[PubMed 1977935]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9030":"<p><b>Title</b> Heparin / Oritavancin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This contraindication applies only to intravenous (IV) unfractionated heparin. The use of subcutaneous heparin is not impacted by this labeled contraindication.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Oritavancin may diminish the therapeutic effect of Heparin. Specifically, oritavancin may artificially increase the results of laboratory tests commonly used to monitor IV heparin effectiveness, which could lead to incorrect decisions to decrease heparin doses. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of intravenous unfractionated heparin within 120 hours (ie, 5 days) following oritavancin administration is contraindicated. The concern is that oritavancin interferes with laboratory monitoring of heparin effects for up to 120 hours after oritavancin administration. Use of subcutaneous heparin, which does not rely on monitoring of the activated partial thromboplastin time (aPTT), is not impacted by this contraindication.</p> \n<p><b>Discussion</b> Concurrent use of intravenous (IV) unfractionated heparin (UFH) within 120 hours following oritavancin administration is contraindicated according to the oritavancin prescribing information.<sup>1</sup> Oritavancin can bind to artificial phospholipids found in coagulation reagents, reducing the in vitro clotting process and resulting in artificially prolonged clotting times. Oritavancin has been shown to artificially prolong aPTT for up to 120 hours and prothrombin time (PT) and international normalized ratio (INR) for 12 hours. No effect of oritavancin was seen in non-phospholipid dependent assays such as chromogenic anti-factor Xa assay.<sup>1</sup><br><br>As oritavancin can falsely elevate aPTT and other common laboratory coagulation tests, incorrect interpretation of such test results may lead to suboptimal anticoagulation and harmful clinical outcomes. This testing interaction appears to be completely responsible for the listed contraindication since oritavancin does not appear associated with either an increased risk for bleeding or hypercoagulability.<sup>1</sup> Subcutaneous heparin does not require aPTT monitoring, so oritavancin can be used in patients using subcutaneous heparin. If testing of heparin effects is necessary during concurrent oritavancin, especially within 120 hours of last oritavancin dose, use of a non-phospholipid dependent test should be considered.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Orbactiv (oritavancin) [prescribing information]. Parsippany, NJ: The Medicines Company; January 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9031":"<p><b>Title</b> Cardiac Glycosides / Parathyroid Hormone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Parathyroid Hormone may enhance the adverse/toxic effect of Cardiac Glycosides. More specifically, Parathyroid Hormone-related hypercalcemia may predispose to digitalis toxicity. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients receiving cardiac glycosides and parathyroid hormone in combination more closely for elevations in serum calcium concentrations, elevations in serum cardiac glycoside concentrations, and clinical evidence of digitalis toxicity.</p>\n<div>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin</p>\n</div> \n<p><b>Discussion</b> Parathyroid hormone US prescribing information recommends that patients treated concomitantly with cardiac glycosides receive monitoring of serum calcium and cardiac glycoside concentrations, and for clinical evidence of digitalis toxicity.<sup>1</sup> Parathyroid hormone-associated hypercalcemia is expected to increase the risk of digitalis toxicity.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Natpara</i> (parathyroid hormone) [prescribing information]. Bedminster, NJ: NPS Pharmaceuticals Inc; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9032":"<p><b>Title</b> Parathyroid Hormone / Alendronate</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alendronate may diminish the therapeutic effect of Parathyroid Hormone. More specifically, Alendronate may interfere with normalization of blood calcium concentrations. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of parathyroid hormone and alendronate.</p> \n<p><b>Discussion</b> Parathyroid hormone US prescribing information recommends against coadministration with alendronate because alendronate may reduce calcium sparing and interfere with normalization of serum calcium concentrations.<sup>1</sup> No specific data are cited in to support this claim, although alendronate, like other bisphosphonates, is expected to decrease the rate of bone resorption.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Natpara</i> (parathyroid hormone) [prescribing information]. Bedminster, NJ: NPS Pharmaceuticals Inc; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9033":"<p><b>Title</b> Prostacyclin Analogues / Thrombolytic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Thrombolytic Agents may enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased risk of bleeding during concomitant use of prostacyclin analogues and thrombolytic agents.</p>\n<div>\n <p><b>Prostacyclin Analogues Interacting Members</b> Beraprost, Epoprostenol, Iloprost, Treprostinil</p>\n <p><b>Thrombolytic Agents Interacting Members</b> Alteplase, Defibrotide, Reteplase, Streptokinase, Tenecteplase, Urokinase</p>\n</div> \n<p><b>Discussion</b> A retrospective evaluation of 31 consecutive patients with primary pulmonary hypertension who were receiving both anticoagulation and epoprostenol reported 11 bleeding episodes in 9 (29%) patients.<sup>1</sup> Of the 11 bleeding episodes, 9 were alveolar in nature.<br><br>Prescribing information for prostacyclin analogues warns that since these agents inhibit platelet aggregation, concomitant use with other drugs that either inhibit platelet aggregation or have anticoagulant properties may increase the risk of bleeding.<sup>2,3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ogawa A, Matsubara H, Fujio H, et al. Risk of alveolar hemorrhage in patients with primary pulmonary hypertension--anticoagulation and epoprostenol therapy. <i>Circ J</i>. 2005;69(2):216-220. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15671616\">[PubMed 15671616]</a></p>\n<p>2. <i>Remodulin</i> (treprostinil) [prescribing information]. Research Triangle Park, NC: United Therapeutics Corp; February 2008.</p>\n<p>3. <i>Flolan</i> (epoprotenol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2011.</p>\n<p>4. <i>Ventavis</i> (iloprost) [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US Inc; November 2013.</p>\n<p>5. <i>Berasil</i> (beraprost) [KR summary of product characteristics]. Http://ezdrug.mfds.go.kr/kfda2?cmd=CCBAA02L2&amp;itemSeq=199400456. Accessed September 1, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9034":"<p><b>Title</b> Endothelin Receptor Antagonists / Beraprost</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Beraprost may enhance the hypotensive effect of Endothelin Receptor Antagonists. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required beyond routine blood pressure monitoring that accompanies the use of beraprost or an endothelin receptor antagonist.</p>\n<div>\n <p><b>Endothelin Receptor Antagonists Interacting Members</b> Ambrisentan, Bosentan, Macitentan</p>\n</div> \n<p><b>Discussion</b> Beraprost prescribing information states that concomitant use of beraprost and an endothelin receptor antagonist may result in an exaggerated hypotensive response due to the vasodilatory effects of both agents.<sup>1</sup> <br><br>In contrast to this warning, in a study of 20 patients receiving nonparenteral prostacyclin analogues (ie, inhaled iloprost or oral beraprost), the addition of the endothelin receptor antagonist bosentan resulted in an improvement in the 6-minute walk test, an increase in peak systolic blood pressure during cardiopulmonary testing, and no instances of symptomatic hypotension or syncope.<sup>2</sup> Guidelines for the treatment of pulmonary arterial hypertension suggest that the combination of prostacyclin analogues and endothelin receptor antagonists may be considered when patients are not responding adequately to initial monotherapy.<sup>3</sup> US prescribing information includes no warnings related to the use of endothelin receptor antagonists and other prostacyclin analogues (eg, iloprost, epoprostenol, treprostinil).<sup>4,5,6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Berasil (beraprost) [KR summary of product characteristics]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199400456. Accessed September 1, 2014.</p>\n<p>2. Hoeper MM, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. <i>Eur Respir J</i>. 2003;22(2):330-334. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12952269\">[PubMed 12952269]</a></p>\n<p>3. McLaughlin VV, Archer SL, Badesch DB, et al; American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association.<i>J Am Coll Cardiol</i>. 2009;53(17):1573-1619. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19389575\">[PubMed 19389575]</a></p>\n<p>4. <i>Remodulin</i> (treprostinil) [prescribing information]. Research Triangle Park, NC: United Therapeutics Corp; February 2008.</p>\n<p>5. <i>Flolan</i> (epoprostenol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2011.</p>\n<p>6. <i>Ventavis</i> (iloprost) [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US Inc; November 2013.</p>\n<p>7. <i>Tracleer</i> (bosentan) [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US Inc; October 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9035":"<p><b>Title</b> Tacrolimus (Systemic) / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ritonavir may increase the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Tacrolimus dosage reductions may be required when starting or altering therapy with ritonavir (either given at a therapeutic dose or when used as a “booster”). Monitor response, plasma concentrations (as appropriate), and for signs of toxicity. Some patients may be maintained on less than 1 mg/week of tacrolimus during coadministration with a protease inhibitor.</p> \n<p><b>Discussion</b> The addition of ritonavir-boosted lopinavir (n=7) or nelfinavir (n=2) to post-liver-transplant patients with stable liver function tests and stable tacrolimus concentrations significantly decreased tacrolimus clearance.<sup>1</sup> Tacrolimus dose requirements were also significantly altered, with lopinavir/ritonavir decreasing tacrolimus dose requirements by 99% and nelfinavir decreasing tacrolimus dose requirements by 75-93%. Similar cases of ritonavir (alone or used as a “booster”) having profound effects on tacrolimus dose requirements have been reported.<sup>2,3,4</sup><br><br>Tacrolimus is metabolized via CYP3A enzymes and subject to transport by p-glycoprotein. Most protease inhibitors are potent inhibitors of CYP3A and inducers of p-glycoprotein.<br><br>One case report describes a dual interaction where lopinavir/ritonavir significantly lowered tacrolimus dose requirement, and tacrolimus significantly increased plasma lopinavir and ritonavir concentrations.<sup>5</sup> Whether this effect is the result of impaired CYP3A metabolism or p-glycoprotein transport, or some other mechanism is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Teicher E, Vincent I, Bonhomme-Faivre L, et al. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. <i>Clin Pharmacokinet</i>. 2007;46(11):941-952. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17922559\">[PubMed 17922559]</a></p>\n<p>2. Jain AB, Venkataramanan R, Eghtesad B, et al. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. <i>Liver Transpl</i>. 2003;9(9):954-960. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12942457\">[PubMed 12942457]</a></p>\n<p>3. Sheikh AM, Wolf DC, Lebovics E, Goldberg R, Horowitz HW. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. <i>Transplantation</i>. 1999;68(2):307-309. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10440408\">[PubMed 10440408]</a></p>\n<p>4. Schonder KS, Shullo MA, Okusanya O. Tacrolimus and lopinavir/ritonavir interaction in liver transplantation. <i>Ann Pharmacother</i>. 2003;37(12):1793-1796. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14632538\">[PubMed 14632538]</a></p>\n<p>5. Guaraldi G, Cocchi S, Codeluppi M, et al. Role of therapeutic drug monitoring in a patient with human immunodeficiency virus infection and end-stage liver disease undergoing orthotopic liver transplantation. <i>Transplant Proc</i>. 2005;37(6):2609-2610. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16182761\">[PubMed 16182761]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9036":"<p><b>Title</b> CYP2D6 Substrates (High risk with Inhibitors) / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients receiving CYP2D6 substrates for increased concentrations and effects of these drugs (or diminished effects of prodrugs) when coadministered with cobicistat. Reduced doses may be required, and should be titrated cautiously. Initiate CYP2D6-metabolized antidepressants at the lowest feasible dose.</p>\n<div>\n <p><b>CYP2D6 Substrates (High risk with Inhibitors) Interacting Members</b> Ajmaline, Amitriptyline, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, AtoMOXetine, Brexpiprazole, Captopril, Carvedilol, Chloroquine, Chlorpheniramine, ChlorproMAZINE, ClomiPRAMINE, Codeine, Dapoxetine, Desipramine*, Deutetrabenazine, Dextromethorphan, Doxepin (Systemic), Doxepin (Topical), DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Eliglustat, Flecainide, FLUoxetine, FluPHENAZine, FluvoxaMINE, Gefitinib, Haloperidol, Iloperidone, Imipramine, Indoramin, Maprotiline, Mequitazine, Methamphetamine, Metoprolol, Mexiletine, Mirtazapine, Nefazodone, Nortriptyline, Olmutinib, PARoxetine, Perhexiline, Perphenazine, Pimozide, Primaquine, Procainamide, Propafenone, Propranolol, Protriptyline, RisperiDONE, Syrian Rue, Tamoxifen, Tetrabenazine, Thioridazine, Timolol (Ophthalmic), Timolol (Systemic), Tolterodine, Trimipramine, Tropisetron, Venlafaxine, Vortioxetine, Zuclopenthixol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in US prescribing information for cobicistat-containing products, coadministration of cobicistat (150 mg daily) increased the maximum concentration and AUC of desipramine (50 mg single dose) by 24% and 65%, respectively.<sup>1,2,3,4</sup> The suspected primary mechanism of this interaction is cobicistat inhibition of CYP2D6-mediated desipramine metabolism. Prescribing information for cobicistat-containing products recommends cautious use with several groups of CYP2D6-metabolized agents, including antidepressants (eg, tricyclics, selective serotonin reuptake inhibitors, trazodone), beta-blockers (eg, metoprolol), antipsychotics (eg, risperidone), and antiarrhythmics (eg, flecainide).<sup>1,2,3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>3. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9037":"<p><b>Title</b> Boceprevir / Cobicistat</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: US prescribing information for the combination product containing elvitegravir, cobicistat, emtricitabine, and tenofovir does not address this potential interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Boceprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of boceprevir with cobicistat. US prescribing information for the combination product containing elvitegravir, cobicistat, emtricitabine, and tenofovir does not address this potential interaction.</p> \n<p><b>Discussion</b> US prescribing information for all cobicistat products except the combination product containing elvitegravir, cobicistat, emtricitabine, and tenofovir states that coadministration of these products with boceprevir is not recommended.<sup>1,2,3,4</sup> The potential mechanism(s) and clinical impact of this interaction are unclear. Boceprevir may theoretically affect exposure to cobicistat and boosted agents via inhibition of their metabolism (eg, via CYP3A4) and/or active transport (eg, via P-glycoprotein). Cobicistat and some boosting agents may increase boceprevir exposure via similar mechanisms.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>3. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9038":"<p><b>Title</b> Telaprevir / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Telaprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of telaprevir with cobicistat. This warning does not apply to use of the combination product containing elvitegravir, cobicistat, emtricitabine, and tenofovir.</p> \n<p><b>Discussion</b> US prescribing information for several cobicistat-containing products states that coadministration of these products with telaprevir is not recommended.<sup>1,2,3</sup> In contrast, US prescribing information for the combination product containing elvitegravir, cobicistat, emtricitabine, and tenofovir states that no significant interaction between this product and telaprevir occurs, citing data from a clinical study in which telaprevir (750 mg 3 times daily) with elvitegravir (150 mg daily) and cobicistat (150 mg daily) had little (less than 25%) or no impact on telaprevir and elvitegravir pharmacokinetic variables.<sup>4</sup> The potential mechanism(s) and clinical impact of this interaction with other products are unclear. Telaprevir may interact with cobicistat (and likely with most boosted agents as well) via mutual inhibition of CYP3A-mediated metabolism. Other mechanisms (eg, mutual inhibition of P-glycoprotein-mediated transport) could also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>3. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9039":"<p><b>Title</b> Budesonide (Nasal) / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Budesonide (Nasal). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider using an alternative nasal corticosteroid when possible, particularly for longer-term concurrent use. If this combination must be used, monitor patients closely for evidence of systemic corticosteroid effects including adrenal suppression.</p> \n<p><b>Discussion</b> Although specific data for cobicistat use with budesonide are not available, US prescribing information for some cobicistat-containing products recommends use of an alternative corticosteroid when possible due to the potential for cobicistat to increase budesonide exposure and adrenal suppression risk.<sup>1,2,3</sup> The suspected primary mechanism of interaction between these agents is cobicistat inhibition of CYP3A-mediated budesonide metabolism. US prescribing information for the elvitegravir, cobicistat, emtricitabine, and tenofovir combination product does not include a warning about this interaction, but does include similar recommendations for concurrent use with orally inhaled fluticasone (also predicted primarily based on cobicistat CYP3A inhibition).<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>3. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9040":"<p><b>Title</b> Bilastine / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Grapefruit Juice may decrease the serum concentration of Bilastine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The bilastine labeling recommends administration one hour before or two hours after consuming any food or fruit juice. Adherence to this recommendation should minimize any potential interaction between bilastine and grapefruit juice or other grapefruit-related product. With any concurrent use monitor for reduced clinical response to bilastine.</p> \n<p><b>Discussion</b> In a clinical study summarized in the United Kingdom bilastine summary of product characteristics, coadministration of grapefruit juice (GFJ) decreased the bioavailability of bilastine (20 mg) by 30%.<sup>1</sup> The postulated mechanism of this interaction is GFJ inhibition of OATP1A2-mediated bilastine uptake.<br><br>Adherence to the labeled recommendation to administer belastine one hour before or two hours after consuming any food or fruit juice should minimize any potential interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ilaxten (bilastine) [summary of product characteristics]. Buckinghamshire, United Kingdom: A Menarini Farmaceutica Internazionale SRL; January 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9041":"<p><b>Title</b> Fluvastatin / Atazanavir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b> (Cobicistat): The specific recommendation associated with this interaction appears in US labeling for atazanavir/cobicistat, but not in labeling for other atazanavir or cobicistat products.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Atazanavir may increase the serum concentration of Fluvastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> When used with atazanavir/cobicistat, initiate fluvastatin at the lowest recommended dose and monitor clinical response (particularly any evidence of toxicity) to dose titration.</p> \n<p><b>Discussion</b> Atazanavir/cobicistat US prescribing information recommends initiating fluvastatin at the lowest recommended dose and monitoring clinical response during fluvastatin dose titration.<sup>1</sup> The potential mechanism of interaction between these agents is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9068":"<p><b>Title</b> Sulfonylureas / Thiazolidinediones</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Thiazolidinediones may enhance the hypoglycemic effect of Sulfonylureas. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider sulfonylurea dose adjustments in patients taking thiazolidinediones. The risk of hypoglycemia with this combination may be greater than the risk with either agent alone.</p>\n<div>\n <p><b>Thiazolidinediones Interacting Members</b> Lobeglitazone, Pioglitazone, Rosiglitazone</p>\n <p><b>Sulfonylureas Interacting Members</b> ChlorproPAMIDE, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, TOLAZamide, TOLBUTamide</p>\n</div> \n<p><b>Discussion</b> In a 16-week clinical study described in the pioglitazone prescribing information, the incidence of hypoglycemia was 3.7% with the combination of pioglitazone and a sulfonylurea compared with 0.5% with a sulfonylurea alone.<sup>1,2</sup> <br><br>Prescribing information for thiazolidinediones warns of the risk of hypoglycemia when combined with oral hypoglycemic agents, particularly with insulin secretagogues such as sulfonyureas.<sup>1,2,3,4</sup> A dose reduction of the sulfonylurea may be necessary. Additionally, prescribing information for rosiglitazone in Canada warns that an increase in fluid retention and heart failure was seen when rosiglitazone was combined with both a sulfonylurea and metformin.<sup>4</sup><br><br>The mechanism of increased hypoglycemia with this combination is likely the result of increased insulin sensitivity due to the thiazolidinedione and increased insulin secretion provided by the sulfonylurea.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Actos</i> (pioglitazone) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; November 2013.</p>\n<p>2. <i>Actos</i> (pioglitazone) [product monograph]. Mississauga, Ontario, Canada: Takeda Canada Inc; March 2012.</p>\n<p>3. <i>Avandia</i> (rosiglitazone) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; May 2014.</p>\n<p>4. <i>Avandia</i> (rosiglitazone) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; January 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9069":"<p><b>Title</b> Insulins / Pioglitazone</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Pioglitazone may enhance the adverse/toxic effect of Insulins. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> If insulin is combined with pioglitazone, insulin dose reductions should be considered to reduce the risk of hypoglycemia. Monitor patients for fluid retention and signs/symptoms of heart failure with this combination.</p>\n<div>\n <p><b>Insulins Interacting Members</b> Insulin (Oral Inhalation), Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Insulin Lispro, Insulin NPH, Insulin Regular</p>\n</div> \n<p><b>Discussion</b> In a 16-week clinical trial described in pioglitazone product labeling, hypoglycemia occurred in 4.8% of patients receiving insulin alone compared with 7.9% and 15.4% of patients who received insulin and pioglitazone, 15 mg and 30 mg, respectively.<sup>1,2</sup><br><br>Product labeling warns that patients who receive insulin and pioglitazone may be at risk for hypoglycemia and an insulin dose reduction may be necessary.<sup>1,2</sup> Product labeling also warns that the risk for fluid retention and exacerbation of heart failure associated with pioglitazone use is increased when used in combination with insulin.<sup>1,2</sup><br><br>The mechanism for increased heart failure events with this combination is unknown. The mechanism for increased hypoglycemia is a result of the pioglitazone-induced increased insulin sensitivity combined with increased insulin due to the exogenous administration of insulin products.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Actos</i> (pioglitazone) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; November 2013.</p>\n<p>2. <i>Actos</i> (pioglitazone) [product monograph]. Mississauga, Ontario, Canada: Takeda Canada Inc; March 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9070":"<p><b>Title</b> Rosiglitazone / Insulins</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Insulins may enhance the adverse/toxic effect of Rosiglitazone. Specifically, the risk of fluid retention, heart failure, and hypoglycemia may be increased with this combination. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The use of rosiglitazone and insulin is not recommended in both US and Canadian prescribing information. The risk of fluid retention, heart failure, and hypoglycemia may be increased with this combination.</p>\n<div>\n <p><b>Insulins Interacting Members</b> Insulin (Oral Inhalation), Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Insulin Lispro, Insulin NPH, Insulin Regular</p>\n</div> \n<p><b>Discussion</b> In pooled clinical trial results described in rosiglitazone prescribing information, heart failure occurred in 2.3% of patients treated with rosiglitazone and insulin compared with 1% of patients treated with insulin alone.<sup>1,2</sup> Although edema and heart failure may occur with the use of rosiglitazone alone, the risk increased when rosiglitazone was added to insulin.<sup>1,2</sup> Additionally, hypoglycemia occurred in 6% of insulin treated patients and 12%-14% of patients treated with the combination of insulin and rosiglitazone. For these safety concerns, product labeling recommends that the combination of rosiglitazone and insulin be avoided.<sup>1,2</sup><br><br>The mechanism for increased heart failure events with this combination is unknown. The mechanism for increased hypoglycemia is a result of the rosiglitazone-induced increased insulin sensitivity combined with increased insulin due to the exogenous administration of insulin products.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Avandia</i> (rosiglitazone) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; May 2014.</p>\n<p>2. <i>Avandia</i> (rosiglitazone) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; January 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9071":"<p><b>Title</b> Insulins / Sodium-Glucose Cotransporter 2 (SLGT2) Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Sodium-Glucose Cotransporter 2 (SLGT2) Inhibitors may enhance the hypoglycemic effect of Insulins. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider a decrease in insulin dose when initiating therapy with a sodium-glucose cotransporter 2 inhibitor and monitor patients for hypoglycemia.</p>\n<div>\n <p><b>Insulins Interacting Members</b> Insulin (Oral Inhalation), Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Insulin Lispro, Insulin NPH, Insulin Regular</p>\n <p><b>Sodium-Glucose Cotransporter 2 (SLGT2) Inhibitors Interacting Members</b> Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin, Ipragliflozin</p>\n</div> \n<p><b>Discussion</b> Manufacturers of all sodium-glucose cotransporter 2 inhibitors warn that the incidence of hypoglycemia increases when coadministered with insulin.<sup>1,2,3,4,5,6</sup> It is recommended to consider insulin dose reductions in patients receiving both agents and to monitor for the development of hypoglycemia.<sup>1,2,3,4,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Invokana</i> (canagliflozin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; May 2014.</p>\n<p>2. <i>Farxiga</i> (dapagliflozin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2014.</p>\n<p>3. <i>Jardiance</i> (empagliflozin) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; August 2015.</p>\n<p>4. <i>Invokana</i> (canagliflozin) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; November 2014.</p>\n<p>5. <i>Forxiga</i> (dapagliflozin) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; December 2014.</p>\n<p>6. Suglat (ipragliflozin) tablets [KR prescribing information]. http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=201404160. Accessed December 15, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9072":"<p><b>Title</b> Sulfonylureas / Sodium-Glucose Cotransporter 2 (SLGT2) Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Sodium-Glucose Cotransporter 2 (SLGT2) Inhibitors may enhance the hypoglycemic effect of Sulfonylureas. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider a decrease in sulfonylurea dose when initiating therapy with a sodium-glucose cotransporter 2 inhibitor and monitor patients for hypoglycemia.</p>\n<div>\n <p><b>Sulfonylureas Interacting Members</b> ChlorproPAMIDE, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, TOLAZamide, TOLBUTamide</p>\n <p><b>Sodium-Glucose Cotransporter 2 (SLGT2) Inhibitors Interacting Members</b> Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin, Ipragliflozin</p>\n</div> \n<p><b>Discussion</b> Manufacturers of all sodium-glucose cotransporter 2 inhibitors warn that the incidence of hypoglycemia increases when coadministered with a sulfonylurea.<sup>1,2,3,4,5,6</sup> It is recommended to consider sulfonylurea dose reductions in patients receiving both agents and to monitor for the development of hypoglycemia.<sup>1,2,3,4,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Invokana</i> (canagliflozin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; May 2014.</p>\n<p>2. <i>Farxiga</i> (dapagliflozin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2014.</p>\n<p>3. <i>Jardiance</i> (empagliflozin) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; August 2015.</p>\n<p>4. <i>Invokana</i> (canagliflozin) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; November 2014.</p>\n<p>5. <i>Forxiga</i> (dapagliflozin) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; December 2014.</p>\n<p>6. Suglat (ipragliflozin) tablets [KR prescribing information]. http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=201404160. Accessed December 15, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9073":"<p><b>Title</b> Cilostazol / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cilostazol. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider reducing the dose of cilostazol to 50 mg twice daily in adult patients who are also receiving strong inhibitors of CYP3A4. Monitor patient response to cilostazol closely.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The cilostazol AUC and maximum serum concentration were increased by an average of 117% and 94%, respectively, when cilostazol (100 mg single dose) was administered on the second day of a 2-day course of the strong CYP3A4 inhibitor ketoconazole (400 mg daily).<sup>1</sup> The cilostazol prescribing information recommends limiting the cilostazol dose to 50 mg twice daily in patients who are receiving strong CYP3A4 inhibitors.<sup>1</sup><br><br>The likely mechanism for this interaction is inhibition of the CYP3A4-mediated metabolism of cilostazol by the strong CYP3A4 inhibitor ketoconazole.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Pletal (cilostazol) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9074":"<p><b>Title</b> Cilostazol / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cilostazol. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider reducing the dose of cilostazol to 50 mg twice daily in adult patients who are also receiving moderate inhibitors of CYP3A4. Monitor patient response to cilostazol closely.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> The cilostazol AUC and maximum serum concentration (Cmax) were increased by an average of 40% to 72% and 30% to 47%, respectively, when cilostazol was administered to individuals who were also receiving the moderate CYP3A4 inhibitors erythromycin or diltiazem.<sup>1,2</sup> The cilostazol Cmax was also an average of 50% higher when given with grapefruit juice (240 mL), but there was no significant change in the cilostazol AUC.<sup>1</sup> One case report describes a 79-year-old man who experienced easy bruising and purpura while taking aspirin, cilostazol, and grapefruit juice (200 mL every other day).<sup>3</sup> His purpura resolved with grapefruit juice discontinuation.<sup>3</sup><br><br>The cilostazol prescribing information recommends limiting the cilostazol dose to 50 mg twice daily in patients who are receiving moderate CYP3A4 inhibitors.<sup>1</sup><br><br>The likely mechanism for this interaction is inhibition of the CYP3A4-mediated metabolism of cilostazol by moderate CYP3A4 inhibitors such as erythromycin, diltiazem, or grapefruit juice.<sup>1</sup> The likely reason for grapefruit juice increasing the cilostazol Cmax but not the cilostazol AUC is inhibition of intestinal CYP3A4 by grapefruit juice, leading to increased cilostazol bioavailability, but relatively little impact of grapefruit juice on hepatic CYP3A4.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pletal (cilostazol) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; July 2015.</p>\n<p>2. Suri A, Forbes WP, Bramer SL. Effects of CYP3A inhibition on the metabolism of cilostazol. <i>Clin Pharmacokinet</i>. 1999;37 Suppl 2:61-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10702888\">[PubMed 10702888]</a></p>\n<p>3. Taniguchi K, Ohtani H, Ikemoto T, Miki A, Hori S, Sawada Y. Possible case of potentiation of the antiplatelet effect of cilostazol by grapefruit juice. <i>J Clin Pharm Ther</i>. 2007;32(5):457-459. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17875111\">[PubMed 17875111]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9075":"<p><b>Title</b> Blood Glucose Lowering Agents / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for excessive pharmacologic effects (e.g., hypoglycemia) in patients receiving monoamine oxidase inhibitors concomitantly with blood glucose lowering agents.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n <p><b>Blood Glucose Lowering Agents Interacting Members</b> Acarbose, Albiglutide, Alogliptin, Anagliptin, Bromocriptine, Canagliflozin, Chloroquine, ChlorproPAMIDE, Dapagliflozin, Disopyramide, Dulaglutide, Empagliflozin, Ertugliflozin, Evogliptin, Exenatide, Gemigliptin, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, Hydroxychloroquine, Insulin (Oral Inhalation), Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Insulin Lispro, Insulin NPH, Insulin Regular, Ipragliflozin, Lanreotide, Linagliptin, Liraglutide, Lixisenatide, Lobeglitazone, Mecasermin, MetFORMIN, MiFEPRIStone, Miglitol, Mitiglinide, Nateglinide, Octreotide, Pasireotide, Pentamidine (Systemic), Perhexiline, Pioglitazone, Pramlintide, QuiNINE, Repaglinide, Rosiglitazone, SAXagliptin, Semaglutide, SITagliptin, Somatostatin Acetate, SulfADIAZINE, Sulfadoxine, Sulfamethoxazole, SulfiSOXAZOLE, SUNItinib, Teneligliptin, TOLAZamide, TOLBUTamide, Vildagliptin, Voglibose</p>\n</div> \n<p><b>Discussion</b> A case report describes a 64 year old male with type 2 diabetes previously stable on antidiabetic therapy (e.g., insulin, glyburide, metformin) who suffered hypoglycemic events within 7 days of initiating linezolid (600 mg BID) for treatment of cellulitis.<sup>1</sup> Another case reports describes a 70 year old male with Parkinson's disease but with no history of diabetes mellitus or hypoglycemia, who suffered a hypoglycemic event 3 weeks after initiating selegiline (5 mg BID).<sup>2</sup> In a study of 35 patients with both diabetes and depressive disorders, a hypoglycemic effect was observed with administration of the monoamine oxidase inhibitor (MAOI) mebanazine, including those patients who were refractory to antidiabetic therapy.<sup>3</sup><br><br>Observations made in animal studies are somewhat mixed in regards to the effects of MAOIs on blood glucose regulation. <br>In rabbits administered insulin and MAOIs, the hypoglycemic effects of insulin were enhanced and prolonged by hydrazine-type MAOIs (mebanazine, phenelzine), but were only prolonged in rabbits receiving a non-hydrazine type MAOI (tranylcypromine).<sup>4</sup> In an in vitro study of the rabbit pancreas, tranylcypromine decreased glucose-stimulated insulin secretion.<sup>5</sup><br><br>The mechanism for the hypoglycemic effects associated with MAOIs is unclear. Some authors suggest the ability of hydrazine-type MAOIs to potentiate insulin secretion may be related to their hydrazine structure and not their MAO inhibitory properties.<sup>5</sup> Hydrazine, while not an MAOI, potentiates insulin secretion. Other authors have proposed that chronic MAO inhibition leads to the release of an ineffective neurotransmitter and a diminished adrenergic response to insulin-induced hypoglycemia.<sup>4</sup><br>Displacement from plasma proteins has also been suggested as a possible mechanism.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bodnar T, Starr K, Halter JB, “Linezolid-Associated Hypoglycemia in a 64-Year Old Man With Type 2 Diabetes,” <i>Am J Geriatr Pharmacother</i>, 2011, 9(1):88-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21459312\">[PubMed 21459312]</a>.</p>\n<p>2. Rowland MJ, Bransome ED, Hendry LB, “Hypoglycemia caused by selegiline, an antiparkinonian drug: can such side effects be predicted?,” <i>J Clin Pharmacol</i>, 1994, 34(1):80-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8132855\">[PubMed 8132855]</a></p>\n<p>3. Wickstrom L, Pettersson K, “Treatment Of Diabetics With Monoamine-Oxidase Inhibitors,” <i>Lancet</i>, 1964, 7;2(7367):995-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14201672\">[PubMed 14201672]</a></p>\n<p>4. Cooper AJ, Ashcroft G, “Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs,” <i>Lancet</i>, 1966, 1(7434): 407-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4159787\">[PubMed 4159787]</a></p>\n<p>5. Feldman JM, Chapman B, “Monoamine Oxidase Inhibitors: Nature of Their Interaction with Rabbit Pancreatic Islets to Alter Insulin Secretion,” <i>Diabetologia</i>, 1975, 11(6):487-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1107123\">[PubMed 1107123]</a></p>\n<p>6. Prescribing information. Amaryl (glimepiride). Bridgewater, NJ: Sanofi-Aventis U.S. L.L.C., May 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9076":"<p><b>Title</b> Blood Glucose Lowering Agents / Salicylates</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction is likely only of concern when using salicylate doses of 3 grams per day or more.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Salicylates may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for excessive pharmacological effect (e.g., hypoglycemia) in patients receiving a salicylate concurrently with a blood glucose lowering agent.This is likely more of a concern in patients receiving salicylates at a dose of 3 grams or greater per day.</p>\n<div>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid, Aspirin, Bismuth Subsalicylate, Choline Magnesium Trisalicylate, Choline Salicylate, Magnesium Salicylate, Salsalate, Sodium Salicylate, Triflusal</p>\n <p><b>Blood Glucose Lowering Agents Interacting Members</b> Acarbose, Albiglutide, Alogliptin, Anagliptin, Bromocriptine, Canagliflozin, Chloroquine, ChlorproPAMIDE, Dapagliflozin, Disopyramide, Dulaglutide, Empagliflozin, Ertugliflozin, Evogliptin, Exenatide, Gemigliptin, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, Hydroxychloroquine, Insulin (Oral Inhalation), Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Insulin Lispro, Insulin NPH, Insulin Regular, Ipragliflozin, Lanreotide, Linagliptin, Liraglutide, Lixisenatide, Lobeglitazone, Mecasermin, MetFORMIN, MiFEPRIStone, Miglitol, Mitiglinide, Nateglinide, Octreotide, Pasireotide, Pentamidine (Systemic), Perhexiline, Pioglitazone, Pramlintide, QuiNINE, Repaglinide, Rosiglitazone, SAXagliptin, Semaglutide, SITagliptin, Somatostatin Acetate, SulfADIAZINE, Sulfadoxine, Sulfamethoxazole, SulfiSOXAZOLE, SUNItinib, Teneligliptin, TOLAZamide, TOLBUTamide, Vildagliptin, Voglibose</p>\n</div> \n<p><b>Discussion</b> The product labeling for various blood glucose lowering agents warn of increased risks of hypoglycemia or need for medication dose adjustment with concurrent use of salicylates.<sup>1,2,3,4,5</sup> Salicylates (3 grams/day or greater) have been observed to enhance the blood glucose lowering effects of sulfonylureas.<sup>6,7,8</sup> Hypoglycemic effects have been reported in both diabetic and nondiabetic patients receiving high dose salicylates (e.g., up to ~6 grams daily).<sup>9,10</sup> Similar effects were not observed in some studies with salicylates at doses up to 2.4 grams/day.<sup>11,12</sup> <br><br>Whether the enhanced hypoglycemic effects reported are the result of a drug interaction or merely cumulative is unclear. Salicylates may influence glucose regulation by several mechanisms including enhanced insulin secretion,<sup>9</sup> reduced hepatic glucose output,<sup>10</sup> and increased insulin sensitization.<sup>10,16</sup> <br>The product labeling for several sulfonylureas propose protein displacement as a possible mechanism for interaction with salicylates.<sup>2,3,4</sup> In vitro, salicylates have been shown to displace tolbutamide and to a much lesser extent glyburide from human albumin.<sup>13</sup>. Concomitant administration of glyburide (5 mg single dose) and high dose aspirin (975 mg QID) in 16 healthy males, increased glyburide free fraction (29%) and clearance (85%) and decreased glyburide AUC (32%).<sup>7</sup> Some authors have demonstrated that for many drugs, protein binding displacement has very little effect on drug exposure.<sup>14</sup><br><br>A pharmacokinetic interaction was not observed in vitro between aspirin and nateglinide.<sup>15</sup> Clinical data and/or interaction studies between salicylates and other hypoglycemic agents appear to be lacking.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Humulin R insulin. Indianapolis, IN: Lilly USA, LLC, March 2011.</p>\n<p>2. Prescribing information. Micronase (glyburide). New York, NY: Pfizer Inc., May 2010.</p>\n<p>3. Prescribing information. Amaryl (glimepiride). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, May 2009.</p>\n<p>4. Prescribing information. Glucotrol (glipizide). New York, NY: Pfizer Inc., August 2010.</p>\n<p>5. Prescribing information. Starlix (nateglinide). East Hanover, NJ: Novartis Pharmaceuticals Corporation, August 2011.</p>\n<p>6. Richardson T, Foster J, and Mawer GE, “Enhancement By Sodium Salicylate of the Blood Glucose Lowering Effect of Chlorpropamide - Drug Interaction or Summation of Similar Effects?” <i>Br J Clin Pharmacol</i>, 1986, 22(1):43-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3527244\">[PubMed 3527244]</a></p>\n<p>7. Kubacka RT, Antal EJ, Juhl RP, et al, “Effects of Aspirin and Ibuprofen on the Pharmacokinetics and Pharmacodynamics of Glyburide in Healthy Subjects,” <i>Ann Pharmacother</i>, 1996, 30(1):20-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8773160\">[PubMed 8773160]</a></p>\n<p>8. Goldfine AB, Fonseca V, Jablonski KA, et al, “The Effects of Salsalate on Glycemic Control in Patients With Type 2 Diabetes,” <i>Ann Intern Med</i>, 2010, 152(6):346-57. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20231565\">[PubMed 20231565]</a></p>\n<p>9. Baron SH, “Salicylates as Hypoglycemic Agents,” <i>Diabetes Care</i>, 1982, 5(1):64-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6754304\">[PubMed 6754304]</a></p>\n<p>10. Hundal RS, Petersen KF, Mayerson AB, et al, “Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes,” <i> J Clin Invest</i>, 2002, 109(10):1321-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12021247\">[PubMed 12021247]</a></p>\n<p>11. Mork NL, Robertson RP, “Effects of Nonsteroidal Antiinflammatory Drugs in Conventional Dosage on Glucose Homeostasis in Patients With Diabetes,” <i> West J Med</i>, 1983, 139(1):46-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6624082\">[PubMed 6624082]</a></p>\n<p>12. Bellet S, Sandberg H, Maeda S, et al,“The Effects of Aspirin Ingestion on Blood Fibrinolysis, Glucose, and Immunoreactive Insulin Levels in Man,” <i>Angiology</i>, 1972, 23(7):445-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5043655\">[PubMed 5043655]</a> </p>\n<p>13. Brown KF and Crooks MJ, “Displacement of Tolbutamide, Glibencalmide and Chlorpropamide From Serum Albumin by Anionic Drugs,” <i>Biochem Pharmacol</i>, 1976, 15, 25(10):1175-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=820348\">[PubMed 820348]</a></p>\n<p>14. Benet LZ and Hoener B, “Changes in Plasma Protein Binding Have Little Clinical Relevance,” <i>Clin Pharmacol Ther</i>, 2002, 71(3):115-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11907485\">[PubMed 11907485]</a></p>\n<p>15. Takanohashi T, Koizumi T, Mihara R, et al, “Prediction of the Metabolic Interaction of Nateglinide with Other Drugs Based on in Vitro Studies,” <i> Drug Metab Pharmacokinet</i>, 2007, 22(6):409-18. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18159128\">[PubMed 18159128]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9077":"<p><b>Title</b> Blood Glucose Lowering Agents / Selective Serotonin Reuptake Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider increased monitoring of glycemic control in patients receiving a blood glucose lowering agent concomitantly with a selective serotonin reuptake inhibitor (SSRI). Dosage adjustments of the blood glucose lowering agent may be necessary upon SSRI initiation or discontinuation.</p>\n<div>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Citalopram, Dapoxetine, Escitalopram, FLUoxetine, FluvoxaMINE, PARoxetine, Sertraline, Vilazodone, Vortioxetine</p>\n <p><b>Blood Glucose Lowering Agents Interacting Members</b> Acarbose, Albiglutide, Alogliptin, Anagliptin, Bromocriptine, Canagliflozin, Chloroquine, ChlorproPAMIDE, Dapagliflozin, Disopyramide, Dulaglutide, Empagliflozin, Ertugliflozin, Evogliptin, Exenatide, Gemigliptin, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, Hydroxychloroquine, Insulin (Oral Inhalation), Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Insulin Lispro, Insulin NPH, Insulin Regular, Ipragliflozin, Lanreotide, Linagliptin, Liraglutide, Lixisenatide, Lobeglitazone, Mecasermin, MetFORMIN, MiFEPRIStone, Miglitol, Mitiglinide, Nateglinide, Octreotide, Pasireotide, Pentamidine (Systemic), Perhexiline, Pioglitazone, Pramlintide, QuiNINE, Repaglinide, Rosiglitazone, SAXagliptin, Semaglutide, SITagliptin, Somatostatin Acetate, SulfADIAZINE, Sulfadoxine, Sulfamethoxazole, SulfiSOXAZOLE, SUNItinib, Teneligliptin, TOLAZamide, TOLBUTamide, Vildagliptin, Voglibose</p>\n</div> \n<p><b>Discussion</b> The U.S. product labeling for regular insulin cautions that selective serotonin reuptake inhibitors (SSRIs) may increase the hypoglycemic effects of insulin.<sup>1</sup> Glimepiride U.S. product labeling includes fluoxetine as a potentially interacting drug that may increase its hypoglycemic effects.<sup>2</sup> Results of two nested case-control studies suggest an increased risk of hypoglycemia in diabetic patients receiving antidepressants that inhibit serotonin reuptake transporter, particularly with long term use (eg, &gt;3 years).<sup>3,4</sup> A review article describes published case reports of hypo- and hyperglycemia associated with some SSRIs.<sup>5</sup><br><br>The mechanism(s) for the proposed drug interaction and/or risk of hypoglycemia is unclear. Authors of some human<sup>6,7</sup> and animal<sup>8</sup> studies have proposed that SSRIs may increase insulin sensitivity. Fluvoxamine inhibits CYP2C9<sup>9</sup> and thus may inhibit sulfonylurea metabolism. Findings from one pharmacokinetic study however, didn’t suggest a clinically meaningful interaction between fluvoxamine and glimepiride.<sup>10</sup> In vitro, other SSRIs have been found to have little or no effect on CYP2C9.<sup>11</sup> Various product labels suggest displacement from protein binding sites as a potential mechanism for drug interaction.<sup>2,12,13,14</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Humulin R (regular human insulin). Indianapolis, IN: Lilly USA, LLC, March 2011.</p>\n<p>2. Prescribing information. Amaryl (glimepiride). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, January 2012.</p>\n<p>3. Derijks HJ, Meyboom RH, Heerdink ER, “The Association Between Antidepressant Use and Disturbances in Glucose Homeostasis: Evidence From Spontaneous Reports,” <i> Eur J Clin Pharmacol</i>, 2008, 64(5): 531-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18196226\">[PubMed 18196226]</a></p>\n<p>4. Derijks HJ, Heerdink ER, De Koning FH, et al, “The Association Between Antidepressant Use and Hypoglycaemia in Diabetic Patients: A Nested Case-Control Study,” <i>Pharmacoepidemiol Drug Saf</i>, 2008, 17(4):336-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18302302\">[PubMed 18302302]</a></p>\n<p>5. Khoza S, Barner JC, “Glucose Dysregulation Associated with Antidepressant Agents: An Analysis of 17 Published Case Reports,” <i>Int J Clin Pharm</i>, 2011, 33(3): 484-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21487738\">[PubMed 21487738]</a></p>\n<p>6. Maheux P, Ducros F, Bourque, et al, “Fluoxetine Improves Insulin Sensitivity in Obese Patients with Non-Insulin-Dependent Diabetes Mellitus Independently of Weight Loss,” <i>Int J Obes Relat Metab Disord</i>, 1997, 21(2):97-102. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9043962\">[PubMed 9043962]</a></p>\n<p>7. Wagner J, Allen NA, Swalley LM, et al, “Depression, Depression Treatment, and Insulin Sensitivity in Adults at Risk for Type 2 Diabetes,” <i>Diabetes Res Clin Pract</i>, 2009, 86(2):96-103. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19720419\">[PubMed 19720419]</a></p>\n<p>8. Park S, Choi SB, “Does Fluoxetine Administration Influence Insulin Resistance in 90% Pancreatized Rats,” <i>Metabolism</i>, 2002, 51(1): 38-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11782870\">[PubMed 11782870]</a></p>\n<p>9. Prescribing information. Luvox CR (fluvoxamine). Palo Alto, CA: Jazz Pharmaceuticals Inc., May 2011.</p>\n<p>10. Niemi M, Backman JT, Neuvonen M, et al, “Effects of Fluconazole and Fluvoxamine on the Pharmacokinetics and Pharmacodynamics of Glimepiride,” <i>Clin Pharmacol Ther</i>, 2001, 69(4): 194-200. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11309547\">[PubMed 11309547]</a></p>\n<p>11. Hemeryck A, De Vriendt C, Belpaire FM, “Inhibition of CYP2C9 by Selective Serotonin Reuptake Inhibitors: In vitro Studies with Tolbutamide and (S)-Warfarin Using Human Liver Microsomes,” <i>Eur J Clin Pharmacol</i>, 1999, 54(12): 947-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10192756\">[PubMed 10192756]</a></p>\n<p>12. Prescribing information. Glucotrol (glipizide). New York, NY: Pfizer Inc., August 2010.</p>\n<p>13. Prescribing information. Prozac (fluoxetine). Indianapolis, IN: Lilly USA, LLC, June 2011.</p>\n<p>14. Prescribing information. Paxil (paroxetine). Weston, Fl: Apotex Corp., July, 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9079":"<p><b>Title</b> Hypoglycemia-Associated Agents / Hypoglycemia-Associated Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Hypoglycemia-Associated Agents may enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Although the concomitant use of two or more drugs that may cause hypoglycemia (either as a therapeutic intention or as an adverse effect) is often clinically appropriate, use of such combinations often substantially increases the risk for hypoglycemia. Monitor patients closely for additive hypoglycemic effects if two or more of these agents are combined.</p>\n<div>\n <p><b>Hypoglycemia-Associated Agents Interacting Members</b> Chloroquine, ChlorproPAMIDE, Disopyramide, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, Hydroxychloroquine, Insulin (Oral Inhalation), Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Insulin Lispro, Insulin NPH, Insulin Regular, Lanreotide, Mecasermin, MiFEPRIStone, Mitiglinide, Nateglinide, Octreotide, Pasireotide, Pentamidine (Systemic), Perhexiline, QuiNINE, Repaglinide, Somatostatin Acetate, SulfADIAZINE, Sulfadoxine, Sulfamethoxazole, SulfiSOXAZOLE, SUNItinib, TOLAZamide, TOLBUTamide</p>\n</div> \n<p><b>Discussion</b> Each drug listed in this monograph is capable of causing clinically significant hypoglycemia independent of other drug therapy. They are included as hypoglycemic agents because they have been reported to cause clinically significant hypoglycemia at a frequency of at least 10%, or have label warnings that suggest an increased risk for hypoglycemia warranting additional monitoring or concomitant medication dose adjustment, or because published literature suggests a significant risk of hypoglycemia with their use. Although numerous factors affect a patient's risk for hypoglycemia (eg, age, nutritional status, renal function) concomitant use of two or more of these drugs may further increase their risk.<sup>1,2,3,4,5</sup> Initial dose reductions of one or both agents should be considered and increased monitoring of blood glucose is advised.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Novolog</i> (insulin aspart) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; January 2015.</p>\n<p>2. <i>Amaryl</i> (glimepiride) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; October 2013.</p>\n<p>3. <i>Sutent</i> (sunitinib) [prescribing information]. New York, NY: Pfizer Inc; December 2014.</p>\n<p>4. Negishi M, Shimomura K, Proks P, Mori M, Shimomura Y. Mechanism of disopyramide-induced hypoglycemia in a patient with type 2 diabetes. <i>Diabet Med</i>. 2009;26(1):76-78. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19125764\">[PubMed 19125764]</a></p>\n<p>5. Seltzer HS. Drug-induced hypoglycemia. A review of 1418 cases. <i>Endocrinol Metab Clin North Am</i>. 1989;18(1):163-183. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2645125\">[PubMed 2645125]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9080":"<p><b>Title</b> Hypoglycemia-Associated Agents / Herbs (Hypoglycemic Properties)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Herbs (Hypoglycemic Properties) may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased risk of hypoglycemia during concomitant use of herbs and drugs that possess such a pharmacologic characteristic.</p>\n<div>\n <p><b>Herbs (Hypoglycemic Properties) Interacting Members</b> Alfalfa, Aloe, Bilberry, Bitter Melon, Burdock, Celery, Damiana, Fenugreek, Garcinia, Garlic, Ginger, Ginseng (American), Gymnema, Marshmallow, Stinging Nettle</p>\n <p><b>Hypoglycemia-Associated Agents Interacting Members</b> Chloroquine, ChlorproPAMIDE, Disopyramide, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, Hydroxychloroquine, Insulin (Oral Inhalation), Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Insulin Lispro, Insulin NPH, Insulin Regular, Lanreotide, Mecasermin, MiFEPRIStone, Mitiglinide, Nateglinide, Octreotide, Pasireotide, Pentamidine (Systemic), Perhexiline, QuiNINE, Repaglinide, Somatostatin Acetate, SulfADIAZINE, Sulfadoxine, Sulfamethoxazole, SulfiSOXAZOLE, SUNItinib, TOLAZamide, TOLBUTamide</p>\n</div> \n<p><b>Discussion</b> Several drugs and herbs possess the ability to lower blood glucose concentrations (either as intentional therapeutic use, or as unintended side effects).<sup>1</sup> The concomitant use of two or more of these agents may result in additive hypoglycemic activity.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hui H, Tang G and Go VL, “Hypoglycemic Herbs and Their Action Mechanisms,” <i>Chin Med</i>, 2009, 4:11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19523223\">[PubMed 19523223]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9081":"<p><b>Title</b> Cilostazol / CYP2C19 Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP2C19 Inhibitors may increase the serum concentration of Cilostazol. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider reducing the dose of cilostazol to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19. Monitor clinical response to cilostazol closely.</p>\n<div>\n <p><b>CYP2C19 Inhibitors Interacting Members</b> Armodafinil, Cimetidine, Esomeprazole, Etravirine, Fluconazole, FLUoxetine, FluvoxaMINE, Ketoconazole (Systemic), Luliconazole, Moclobemide, Modafinil, Omeprazole, Parecoxib, Stiripentol, Ticlopidine, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The AUC of OPC-13015, an active metabolite of cilostazol, increased 69% in a study of 20 healthy subjects who received a single dose of cilostazol (100 mg) on day 8 of a 12-day course of the moderate CYP2C19 inhibitor omeprazole (40 mg daily).<sup>1,2</sup> The AUC of cilostazol increased by an average of 26%. Cilostazol appears to be primarily metabolized via CYP3A4, with secondary contribution from CYP2C19.<sup>2</sup> OPC-13015 is primarily metabolized via CYP2C19. The cilostazol prescribing information recommends limiting the cilostazol dose to 50 mg twice daily in patients who are receiving CYP2C19 inhibitors.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Suri A, Bramer SL. Effect of omeprazole on the metabolism of cilostazol. <i>Clin Pharmacokinet</i>. 1999;37 Suppl 2:53-59. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10702887\">[PubMed 10702887]</a></p>\n<p>2. <i>Pletal</i> (cilostazol) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9082":"<p><b>Title</b> Hypoglycemia-Associated Agents / Antidiabetic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Although the concomitant use of antidiabetic agents and drugs that cause hypoglycemia is often clinically appropriate, use of such combinations often substantially increases the risk for hypoglycemia. Monitor patients closely for hypoglycemic effects if these agents are combined.</p>\n<div>\n <p><b>Antidiabetic Agents Interacting Members</b> Acarbose, Albiglutide, Alogliptin, Anagliptin, Bromocriptine, Canagliflozin, ChlorproPAMIDE, Dapagliflozin, Dulaglutide, Empagliflozin, Ertugliflozin, Evogliptin, Exenatide, Gemigliptin, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, Insulin (Oral Inhalation), Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Insulin Lispro, Insulin NPH, Insulin Regular, Ipragliflozin, Linagliptin, Liraglutide, Lixisenatide, Lobeglitazone, MetFORMIN, Miglitol, Mitiglinide, Nateglinide, Pioglitazone, Pramlintide, Repaglinide, Rosiglitazone, SAXagliptin, Semaglutide, SITagliptin, Teneligliptin, TOLAZamide, TOLBUTamide, Vildagliptin, Voglibose</p>\n <p><b>Hypoglycemia-Associated Agents Interacting Members</b> Chloroquine, ChlorproPAMIDE, Disopyramide, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, Hydroxychloroquine, Insulin (Oral Inhalation), Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Insulin Lispro, Insulin NPH, Insulin Regular, Lanreotide, Mecasermin, MiFEPRIStone, Mitiglinide, Nateglinide, Octreotide, Pasireotide, Pentamidine (Systemic), Perhexiline, QuiNINE, Repaglinide, Somatostatin Acetate, SulfADIAZINE, Sulfadoxine, Sulfamethoxazole, SulfiSOXAZOLE, SUNItinib, TOLAZamide, TOLBUTamide</p>\n</div> \n<p><b>Discussion</b> Although many antidiabetic agents have a low incidence of hypoglycemia when used as monotherapy, the risk of hypoglycemia is often increased when combined with agents known to cause hypoglycemia (eg, insulin, sulfonlyureas).<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14,15</sup> This increased risk of hypoglycemia is often greater than with use of the hypoglycemic agent alone. While the increased risk of hypoglycemia has been documented most often with the use of insulin and sulfonylureas, other agents that carry a significant risk of hypoglycemia (ie, those agents included as hypoglycemic agents in this monograph) should also be used with caution when combined with other antidiabetic agents capable of lowering blood glucose.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Byetta</i> (exenatide) [prescribing information]. San Diego, CA: Amylin Pharmaceuticals Inc; October 2009.</p>\n<p>2. <i>Victoza</i> (liraglutide) [prescribing information]. Princeton, NJ: Novo Nordisk Inc; January 2010.</p>\n<p>3. <i>Tanzeum</i> (albiglutide) [prescribing information]. Wilmington, DE: GlaxoSmithKline LLC; April 2014.</p>\n<p>4. <i>Trulicity</i> (dulaglutide) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; September 2014.</p>\n<p>5. <i>Lyxumia</i> (lixisenatide) [summary of product characteristics]. Singapore: Sanofi-Aventis Singapore; October 2014.</p>\n<p>6. <i>Invokana</i> (canagliflozin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; May 2014.</p>\n<p>7. <i>Farxiga</i> (dapagliflozin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2014.</p>\n<p>8. <i>Jardiance</i> (empagliflozin) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; August 2015.</p>\n<p>9. <i>Symlin</i> (pramlintide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP, June 2014.</p>\n<p>10. <i>Actos</i> (pioglitazone) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; November 2013.</p>\n<p>11. <i>Avandia</i> (rosiglitazone) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; May 2014.</p>\n<p>12. <i>Precose</i> (acarbose) [prescribing information]. Wayne, NJ: Bayer Healthcare Pharmaceuticals Inc; November 2011.</p>\n<p>13. <i>Glyset</i> (miglitol) [prescribing information]. New York, NY: Pfizer Inc; August 2012.</p>\n<p>14. <i>Cycloset</i> (bromocriptine) [prescribing information]. Tiverton, RI: VeroScience LLC; September 2010.</p>\n<p>15. Suglat (ipragliflozin) tablets [KR prescribing information]. http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=201404160. Accessed December 15, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9083":"<p><b>Title</b> Lovastatin / Cilostazol</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Lovastatin may decrease the serum concentration of Cilostazol. Cilostazol may increase the serum concentration of Lovastatin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The cilostazol AUC and maximum serum concentration were decreased by an average of 15% with concurrent lovastatin (80 mg) in a study of 15 healthy volunteers.<sup>1,2</sup> Cilostazol metabolite concentrations were also reportedly decreased to a nonsignificant degree.<br><br>The AUC of both lovastatin and its beta-hydroxy metabolite were increased by approximately 1.6- to 2-fold with concurrent cilostazol (100 mg twice daily or 150 mg single dose).<sup>1,2</sup> This increase was characterized as likely clinically insignificant by the cilostazol prescribing information.<sup>1</sup><br><br>The specific mechanism for these interactions is uncertain. Both agents are at least partially dependent on CYP3A4 for their metabolism, but neither has been shown to be a significant inhibitor or inducer of CYP3A4.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Pletal</i> (cilostazol) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; January 2015.</p>\n<p>2. Bramer SL, Brisson J, Corey AE, Mallikaarjun S. Effect of multiple cilostazol doses on single dose lovastatin pharmacokinetics in healthy volunteers. <i>Clin Pharmacokinet</i>. 1999;37 Suppl 2:69-77. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10702889\">[PubMed 10702889]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9084":"<p><b>Title</b> CYP2C8 Substrates (High risk with Inhibitors) / Abiraterone Acetate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Abiraterone Acetate may increase the serum concentration of CYP2C8 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use caution with concurrent use of abiraterone and any CYP2C8 substrate, particularly for those agents that have a narrow therapeutic index. Monitor patient response to the CYP2C8 substrate closely.</p>\n<div>\n <p><b>CYP2C8 Substrates (High risk with Inhibitors) Interacting Members</b> Amiodarone, Amodiaquine, Dabrafenib, Dasabuvir, Enzalutamide, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Pioglitazone, Repaglinide, Rosiglitazone, Selexipag</p>\n</div> \n<p><b>Discussion</b> The AUC of the CYP2C8 substrate pioglitazone was increased by an average of 46% in a study of healthy subjects who were given pioglitazone together with a single dose of abiraterone (1000 mg).<sup>1</sup><br><br>The likely mechanism for this interaction is inhibition of the CYP2C8-mediated metabolism of pioglitazone by abiraterone. Caution is advised for any narrow therapeutic index CYP2C8 substrate that is given together with abiraterone.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zytiga</i> (abiraterone acetate) [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9085":"<p><b>Title</b> Blood Glucose Lowering Agents / Androgens</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Androgens may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for hypoglycemia and/or decreased requirements of blood glucose lowering agents when combined with androgens.</p>\n<div>\n <p><b>Androgens Interacting Members</b> Fluoxymesterone, Mesterolone, MethylTESTOSTERone, Nandrolone, Oxandrolone, Oxymetholone, Testosterone<br><b>Exception</b> Danazol</p>\n <p><b>Blood Glucose Lowering Agents Interacting Members</b> Acarbose, Albiglutide, Alogliptin, Anagliptin, Bromocriptine, Canagliflozin, Chloroquine, ChlorproPAMIDE, Dapagliflozin, Disopyramide, Dulaglutide, Empagliflozin, Ertugliflozin, Evogliptin, Exenatide, Gemigliptin, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, Hydroxychloroquine, Insulin (Oral Inhalation), Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Insulin Lispro, Insulin NPH, Insulin Regular, Ipragliflozin, Lanreotide, Linagliptin, Liraglutide, Lixisenatide, Lobeglitazone, Mecasermin, MetFORMIN, MiFEPRIStone, Miglitol, Mitiglinide, Nateglinide, Octreotide, Pasireotide, Pentamidine (Systemic), Perhexiline, Pioglitazone, Pramlintide, QuiNINE, Repaglinide, Rosiglitazone, SAXagliptin, Semaglutide, SITagliptin, Somatostatin Acetate, SulfADIAZINE, Sulfadoxine, Sulfamethoxazole, SulfiSOXAZOLE, SUNItinib, Teneligliptin, TOLAZamide, TOLBUTamide, Vildagliptin, Voglibose</p>\n</div> \n<p><b>Discussion</b> Product labeling for several androgens warns that changes in insulin sensitivity or glycemic control may occur in patients treated with androgens. The metabolic effects of androgens may decrease blood glucose, and therefore, may decrease insulin and/or antidiabetic agent requirements or lead to hypoglycemia.<sup>1,2,3,4,5</sup> Product labeling for various blood glucose lowering agents also warns that concomitant androgen use may increase the risk for hypoglycemia or need for medication dose reduction.<sup>6,7,8,9</sup> <br><br>Treatment with testosterone has improved diabetic control in several randomized, controlled trials.<sup>10,11,12,13</sup> In contrast, other reports show no effect of testosterone on measures of glycemic control.<sup>14,15,16</sup> Meta-analyses suggest that testosterone replacement improves measures of glycemic control.<sup>17,18</sup> Other androgens have also been reported to improve insulin sensitivity.<sup>19,20</sup> <br><br>Of note, insulin resistance has also been reported with androgen use, particularly in women and with the androgen danazol.<sup>21,22,23,24</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Testosterone gel [prescribing information]. Allegan, MI: Perrigo-Israel Pharmaceuticals Ltd; January 2013.</p>\n<p>2. <i>Testred</i> (methyltestosterone) [prescribing information]. Aliso Viejo, CA: Valeant Pharmaceuticals North America; November 2007.</p>\n<p>3. <i>Androxy</i> (fluoxymesterone) [prescribing information]. Minneapolis, MN: Upsher-Smith Laboratories Inc; May 2004.</p>\n<p>4. <i>Anadrol</i> (oxymetholone) [prescribing information]. Marietta, GA: Unimed Pharmaceuticals Inc; August 2004. </p>\n<p>5. <i>Deca Durabolin</i> (nandrolone) [summary of product characteristics]. Milton Road, Cambridge, England: Organon Laboratories Limited; February 2012. </p>\n<p>6. <i>Novolog</i> (insulin aspart) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; January 2015.</p>\n<p>7. <i>Symlin</i> (pramlintide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; June 2014.</p>\n<p>8. <i>Amaryl</i> (glimepiride) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; October 2013.</p>\n<p>9. <i>Prandin</i> (repaglinide) [prescribing information]. Princeton, NJ: Novo Nordisk Inc; March 2012.</p>\n<p>10. Boyanov M, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. <i>Aging Male</i>. 2003;6(1):1-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12809074\">[PubMed 12809074]</a></p>\n<p>11. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. <i>Eur J Endocrinol</i>. 2006;154(6):899-906. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16728551\">[PubMed 16728551]</a></p>\n<p>12. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. <i>J Androl</i>. 2009;30(6):726-733. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19578132\">[PubMed 19578132]</a></p>\n<p>13. Jones TH, Arver S, Behre HM, et al; TIMES2 Investigators. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). <i>Diabetes Care</i>. 2011;34(4):828-837. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21386088\">[PubMed 21386088]</a></p>\n<p>14. Lee CH, Kuo SW, Hung YJ, et al. The effect of testosterone supplement on insulin sensitivity, glucose effectiveness, and acute insulin response after glucose load in male type 2 diabetics. <i>Endocr Res</i>. 2005;31(2):139-148. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16353672\">[PubMed 16353672]</a></p>\n<p>15. Basu R, Dalla Man C, Campioni M, et al. Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men. <i>Diabetes Care</i>. 2007;30(8):1972-1978. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17496236\">[PubMed 17496236]</a></p>\n<p>16. Gopal RA, Bothra N, Acharya SV, et al. Treatment of hypogonadism with testosterone in patients with type 2 diabetes mellitus. <i>Endocr Pract</i>. 2010;16(4):570-576. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20150021\">[PubMed 20150021]</a></p>\n<p>17. Corona G, Monami M, Rastrelli G, et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. <i>Int J Androl</i>. 2011;34(6 pt 1):528-540. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20969599\">[PubMed 20969599]</a></p>\n<p>18. Cai X, Tian Y, Wu T, Cao CX, Li H, Wang KJ. Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. <i>Asian J Androl</i>. 2014;16(1):146-152. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24369149\">[PubMed 24369149]</a></p>\n<p>19. Hobbs CJ, Jones RE, Pymate SR. Nandrolone, a 19-nortestosterone, enhances insulin-independent glucose uptake in normal men. <i>J Clin Endocrinol Metab</i>. 1996;81(4):1582-1585. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8636371\">[PubMed 8636371]</a></p>\n<p>20. Aramwit P, Kobpipat N, Satirapoj B, Kopple JD, Supasyndh O. Oxymetholone ameliorates insulin sensitivity in maintenance hemodialysis patients: a randomized controlled trial. <i>Clin Nephrol</i>. 2009;71(4):413-422. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19356374\">[PubMed 19356374]</a></p>\n<p>21. Matalliotakis I, Panidis D, Vlassis G, Neonaki M, Koumantakis E. Decreased sensitivity to insulin during treatment with danazol in women with endometriosis. <i>Clin Exp Obstet Gynecol</i>. 1997;24(3):160-162. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9478307\">[PubMed 9478307]</a></p>\n<p>22. Seifer DB, Freedman LN, Cavender JR, Baker RA. Insulin-dependent diabetes mellitus associated with danazol. <i>Am J Obstet Gynecol</i>. 1990;162(2):474-475. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2309833\">[PubMed 2309833]</a></p>\n<p>23. Bruce R, Godsland I, Stevenson J, et al. Danazol induces resistance to both insulin and glucagon in young women. <i>Clin Sci (Lond)</i>. 1992;82(2):211-217. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1311660\">[PubMed 1311660]</a></p>\n<p>24. <i>Danocrine</i> (danazol) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; December 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9086":"<p><b>Title</b> Blood Glucose Lowering Agents / Pegvisomant</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pegvisomant may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of hypoglycemia if pegvisomant is added to a blood glucose lowering agent containing regimen. A reduction in the dosage of the blood glucose lowering agent may be needed.</p>\n<div>\n <p><b>Blood Glucose Lowering Agents Interacting Members</b> Acarbose, Albiglutide, Alogliptin, Anagliptin, Bromocriptine, Canagliflozin, Chloroquine, ChlorproPAMIDE, Dapagliflozin, Disopyramide, Dulaglutide, Empagliflozin, Ertugliflozin, Evogliptin, Exenatide, Gemigliptin, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, Hydroxychloroquine, Insulin (Oral Inhalation), Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Insulin Lispro, Insulin NPH, Insulin Regular, Ipragliflozin, Lanreotide, Linagliptin, Liraglutide, Lixisenatide, Lobeglitazone, Mecasermin, MetFORMIN, MiFEPRIStone, Miglitol, Mitiglinide, Nateglinide, Octreotide, Pasireotide, Pentamidine (Systemic), Perhexiline, Pioglitazone, Pramlintide, QuiNINE, Repaglinide, Rosiglitazone, SAXagliptin, Semaglutide, SITagliptin, Somatostatin Acetate, SulfADIAZINE, Sulfadoxine, Sulfamethoxazole, SulfiSOXAZOLE, SUNItinib, Teneligliptin, TOLAZamide, TOLBUTamide, Vildagliptin, Voglibose</p>\n</div> \n<p><b>Discussion</b> Prescribing information for pegvisomant warns that since pegvisomant blocks the actions of growth hormone, glucose tolerance and glycemic control may improve.<sup>1</sup> Blood sugar should be carefully monitored and doses of blood glucose lowering agents may need to be reduced to avoid hypoglycemia.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Somavert</i> (pegvisomant) [prescribing information]. New York, NY: Pfizer Inc; December 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9087":"<p><b>Title</b> Cobicistat / Primidone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Primidone may decrease the serum concentration of Cobicistat. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of cobicistat-containing products and primidone due to the potential for decreased antiviral concentrations and effectiveness and the associated increased risk for viral resistance. Concomitant use with phenobarbital, the active metabolite of primidone, is listed as contraindicated in most cobicistat product labels.</p> \n<p><b>Discussion</b> Although specific data for cobicistat with phenobarbital are not available, the prescribing information for most cobicistat-containing products lists concomitant use with phenobarbital as contraindicated due to the potential for decreased antiviral concentrations and effectiveness and the associated increased risk for viral resistance to these agents.<sup>1,2,3,4</sup> Labeling for cobicistat/darunavir recommends consideration of alternative antiepileptics when possible, but does not list phenobarbital use as contraindicated.<sup>5</sup><br><br>The likely mechanism for this predicted interaction is phenobarbital induction of the CYP3A-mediated metabolism of cobicistat, which is used in combination with antiviral agents to increase their systemic exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; July 2015.</p>\n<p>2. Tybost (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2015.</p>\n<p>3. Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2015. </p>\n<p>4. Evotaz (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; July 2015.</p>\n<p>5. Prezcobix (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9088":"<p><b>Title</b> Everolimus / Fenofibrate and Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fenofibrate and Derivatives may decrease the serum concentration of Everolimus. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> When using fenofibrate together with everolimus monitor response to everolimus closely, including both everolimus whole blood concentrations and clinical evidence of everolimus response.</p> \n<p><b>Discussion</b> Everolimus trough plasma concentration decreased from 10.1 ng/mL to 4.2 ng/mL 2 weeks after a 57-year-old patient who had been taking everolimus 10mg/day initiated fenofibrate 160mg/day.<sup>1</sup> After discontinuation of fenofibrate, everolimus trough plasma concentration increased to 11.5 ng/mL.<br><br>Whether this decrease in everolimus concentrations truly reflects an interaction with fenofibrate is uncertain, but the authors of this case report attribute this to fenofibrate induction of the CYP3A4-mediated metabolism of everolimus.<sup>1</sup> Fenofibrate is not widely regarded as an inducer of CYP3A4, but fenofibric acid prescribing information does note a 8% to 17% decrease in the AUC of the CYP3A4 substrates efavirenz and atorvastatin, suggestive of possible weak induction of CYP3A4.<sup>2</sup> It is unclear, however, if such a weak inducing effect could account for the substantial decrease in everolimus concentrations reported in this published case report.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mir O, Poinsignon V, Arnedos M, Delaloge S, Paci A. Pharmacokinetic interaction involving fenofibrate and everolimus. <i>Ann Oncol</i>. 2015;26(1):248-249. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25361989\">[PubMed 25361989]</a></p>\n<p>2. <i>Fibricor</i> (fenofibric acid) [prescribing information]. Philadelphia, PA: Mutual Pharmaceutical Company, Inc.; January 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9089":"<p><b>Title</b> Blood Glucose Lowering Agents / Quinolones</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Quinolones may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for evidence of hypo- or hyperglycemia during concomitant administration of blood glucose lowering agents and quinolone antibiotics. Systemic gatifloxacin appears to pose the highest risk, but caution seems warranted with all quinolones. The risk of hypoglycemia appears greatest during the first few days of antibiotic therapy, while the risk of hyperglycemia is greater after several days of therapy.</p>\n<div>\n <p><b>Quinolones Interacting Members</b> Ciprofloxacin (Systemic), Delafloxacin, Gemifloxacin, LevoFLOXacin (Oral Inhalation), LevoFLOXacin (Systemic), Lomefloxacin, Moxifloxacin (Systemic), Nalidixic Acid, Norfloxacin, Ofloxacin (Systemic), Pefloxacin, Pipemidic Acid, Sparfloxacin</p>\n <p><b>Blood Glucose Lowering Agents Interacting Members</b> Acarbose, Albiglutide, Alogliptin, Anagliptin, Bromocriptine, Canagliflozin, Chloroquine, ChlorproPAMIDE, Dapagliflozin, Disopyramide, Dulaglutide, Empagliflozin, Ertugliflozin, Evogliptin, Exenatide, Gemigliptin, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, Hydroxychloroquine, Insulin (Oral Inhalation), Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Insulin Lispro, Insulin NPH, Insulin Regular, Ipragliflozin, Lanreotide, Linagliptin, Liraglutide, Lixisenatide, Lobeglitazone, Mecasermin, MetFORMIN, MiFEPRIStone, Miglitol, Mitiglinide, Nateglinide, Octreotide, Pasireotide, Pentamidine (Systemic), Perhexiline, Pioglitazone, Pramlintide, QuiNINE, Repaglinide, Rosiglitazone, SAXagliptin, Semaglutide, SITagliptin, Somatostatin Acetate, SulfADIAZINE, Sulfadoxine, Sulfamethoxazole, SulfiSOXAZOLE, SUNItinib, Teneligliptin, TOLAZamide, TOLBUTamide, Vildagliptin, Voglibose</p>\n</div> \n<p><b>Discussion</b> Product labeling, case reports, and published studies have described an association between several quinolone antibiotics and glucose homeostasis abnormalities (i.e., hypo- and hyperglycemia) both independent of and in conjunction with other glucose-altering medications. Hyperglycemia associated with quinolones appears to be several-fold more common than hypoglycemia, accounting for 80-91% of all patients with any glucose abnormality in two retrospective studies.<sup>1,2</sup> The risk of abnormal glucose homeostasis does not appear to be equivalent among all quinolones, as systemic gatifloxacin appears to have a substantially greater risk than other quinolones,<sup>1,3,4,5</sup> though levofloxacin, ciprofloxacin, ofloxacin, and norfloxacin have also been implicated.<sup>2,4,5,6,7,8,9,10</sup><br><br>Blood glucose lowering agents (alone and in combinations) have been associated with an increased risk of both hypoglycemia and hyperglycemia with concurrent quinolone antibiotics.<sup>1,2,3,5</sup> Of note, diabetes itself has also been identified as a risk factor for quinolone-associated glucose homeostasis abnormalities.<sup>1,2,5</sup><br><br>Quinolones appear to have dual effects on pancreatic islet cells, initially stimulating insulin release but inhibiting insulin release after long-term exposure.<sup>11,12,13,14</sup> Data from studies showing that hypoglycemic effects usually occur within 1-2 days of initiating quinolone therapy while hyperglycemic effects tend to occur later in therapy lend support to this proposed mechanism.<sup>1,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lodise T, Graves J, Miller C, et al, “Effects of Gatifloxacin and Levofloxacin on Rates of Hypoglycemia and Hyperglycemia among Elderly Hospitalized Patients,” <i>Pharmacotherapy</i>, 2007, 27:1498-505. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17963459\">[PubMed 17963459]</a></p>\n<p>2. Mohr JF, McKinnon PS, Peymann PJ, et al, “A Retrospective, Comparative Evaluation of Dysglycemias in Hospitalized Patients Receiving Gatifloxacin, Levofloxacin, Ciprofloxacin, or Ceftriaxone,” <i>Pharmacotherapy</i>, 2005, 25:1303-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16185173\">[PubMed 16185173]</a></p>\n<p>3. Graumlich JF, Habis S, Avelino RR, et al, “Hypoglycemia in Inpatients after Gatifloxacin or Levofloxacin Therapy: Nested Case-Control Study,” <i>Pharmacotherapy</i>, 2005, 25:1296-302. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16185172\">[PubMed 16185172]</a></p>\n<p>4. Frothingham R, “Glucose Homeostasis Abnormalities Associated with Use of Gatifloxacin,” <i>Clin Infect Dis</i>, 2005, 41:1269-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16206101\">[PubMed 16206101]</a></p>\n<p>5. Park-Wyllie LY, Juurlink DN, Kopp A, et al, “Outpatient Gatifloxacin Therapy and Dysglycemia in Older Adults,” <i>N Engl J Med</i>, 2006, 354(13):1352-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16510739\">[PubMed 16510739]</a></p>\n<p>6. Roberge RJ, Kaplan R, Frank R, et al, “Glyburide-Ciprofloxacin Interaction With Resistant Hypoglycemia,” <i>Ann Emerg Med</i>, 2000, 36(2):160-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10918110\">[PubMed 10918110]</a></p>\n<p>7. Lin G, Hays DP, and Spillane L, “Refractory Hypoglycemia From Ciprofloxacin and Glyburide Interaction,” <i>J Toxicol Clin Toxicol</i>, 2004, 42(3):295-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15362597\">[PubMed 15362597]</a></p>\n<p>8. Friedrich LV and Dougherty R, “Fatal Hypoglycemia Associated with Levofloxacin,” <i>Pharmacotherapy</i>, 2004, 24(12):1807-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15585448\">[PubMed 15585448]</a></p>\n<p>9. Noroxin [package insert]. Whitehouse Station, NJ: Merck &amp; Co, 2004.</p>\n<p>10. Floxin [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc, 2004.</p>\n<p>11. Maeda N, Tamagawa T, Niki I, et al, “Increase in Insulin Release From Rat Pancreatic Islets by Quinolone Antibiotics,” <i>Br J Pharmacol</i>, 1996, 117(2):372-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8789393\">[PubMed 8789393]</a></p>\n<p>12. Zunkler BJ and Wos M, “Effects of Lomefloxacin and Norfloxacin on Pancreatic Beta-Cell ATP-Sensitive K(+) Channels,” <i>Life Sci</i>, 2003, 73(4):429-35. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12759137\">[PubMed 12759137]</a></p>\n<p>13. Tomita T, Onishi M, Sato E, et al, “Gatifloxacin Induces Augmented Insulin Release and Intracellular Insulin Depletion of Pancreatic Islet Cells,” <i>Biol Pharm Bull</i>, 2007, 30:644-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17409495\">[PubMed 17409495]</a></p>\n<p>14. Yamada C, Nagashima K, Takahashi A, et al, “Gatifloxacin Acutely Stimulates Insulin Secretion and Chronically Suppresses Insulin Biosynthesis,” <i>Eur J Pharmacol</i>, 2006, 553:67-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17070519\">[PubMed 17070519]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9090":"<p><b>Title</b> Blood Glucose Lowering Agents / Angiotensin-Converting Enzyme Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Angiotensin-Converting Enzyme Inhibitors may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> No action required. Regular hypoglycemia education and monitoring (that accompanies use of blood glucose lowering agents) should be sufficient for management of this possible interaction.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n <p><b>Blood Glucose Lowering Agents Interacting Members</b> Acarbose, Albiglutide, Alogliptin, Anagliptin, Bromocriptine, Canagliflozin, Chloroquine, ChlorproPAMIDE, Dapagliflozin, Disopyramide, Dulaglutide, Empagliflozin, Ertugliflozin, Evogliptin, Exenatide, Gemigliptin, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, Hydroxychloroquine, Insulin (Oral Inhalation), Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Insulin Lispro, Insulin NPH, Insulin Regular, Ipragliflozin, Lanreotide, Linagliptin, Liraglutide, Lixisenatide, Lobeglitazone, Mecasermin, MetFORMIN, MiFEPRIStone, Miglitol, Mitiglinide, Nateglinide, Octreotide, Pasireotide, Pentamidine (Systemic), Perhexiline, Pioglitazone, Pramlintide, QuiNINE, Repaglinide, Rosiglitazone, SAXagliptin, Semaglutide, SITagliptin, Somatostatin Acetate, SulfADIAZINE, Sulfadoxine, Sulfamethoxazole, SulfiSOXAZOLE, SUNItinib, Teneligliptin, TOLAZamide, TOLBUTamide, Vildagliptin, Voglibose</p>\n</div> \n<p><b>Discussion</b> Case reports have described episodes of hypoglycemia in diabetic patients attributed to an interaction between antidiabetic medications and angiotensin converting enzyme (ACE) inhibitors.<sup>1,2,3</sup> In support of the theories proposed in these cases, one small study in healthy volunteers (n=9) found that enalapril enhanced the glucose-lowering effect of the sulfonylurea glibenclamide.<sup>4</sup> Additionally, a review of reported cases of hypoglycemia in the French Pharmacovigilance database found evidence of an association between concurrent antidiabetic medications and ACE inhibitors with hypoglycemia.<sup>5</sup> Two case-control studies have also found significant associations between hypoglycemia and the combination of antidiabetic medications and ACE inhibitors (reported odds ratios of 2.8-3.2).<sup>6,7</sup><br><br>In contrast to the above reports, other studies have concluded serum ACE activity is positively associated with the risk of hypoglycemia in diabetic patients,<sup>8,9</sup> that captopril does not alter the normal physiologic response to hypoglycemia,<sup>10</sup> and that ACE inhibitor or angiotensin II receptor blocker therapy actually decreases the risk of clinical hypoglycemia in insulin-treated diabetic patients.<sup>11</sup> Also, a cohort study of 13,559 insulin- or sulfonylurea-treated elderly patients found no association between specific antihypertensive medications (including ACE inhibitors) and episodes of hypoglycemia (total of 598 hypoglycemic episodes evaluated).<sup>12</sup> One case-control study of patients who were hospitalized due to hypoglycemia (cases, n=404; n=1375 matched controls) found no overall association between ACE inhibitors and hypoglycemia, though they did find an association with the specific ACE inhibitor enalapril (odds ratio (95% CI) = 2.4 (1.1-5.3)).<sup>13</sup> <br><br>The mechanism of any interaction is unknown. Apart from concurrent antidiabetic medication ACE inhibitors have been associated with hypoglycemia in case reports.<sup>14,15</sup> Also, ACE inhibitors have been found to have various effects on both islet structure and function as well as on the physiologic response to hypoglycemia.<sup>16,17,18</sup> Whether these and/or other mechanisms are involved in any interaction between ACEIs and blood glucose lowering agents is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rett K, Wicklmayr M, Dietze GJ, “Hypoglycemia in Hypertensive Diabetic Patients Treated with Sulfonylureas, Biguanides, and Captopril,” <i>N Engl J Med</i>, 1988, 319:1609.</p>\n<p>2. Arauz-Pacheco C, Ramirez LC, Rios JM, et al, “Hypoglycemia Induced by Angiotensin-Converting Enzyme Inhibitors in Patients with Non-Insulin-Dependent Diabetes Receiving Sulfonylurea Therapy,” <i>Am J Med</i>, 1990, 89:811-3.</p>\n<p>3. Sakaguchi H, Maeda S, Fukunaga Y, et al, “Hypoglycemia Associated with the Administration of Angiotensin-Converting Enzyme Inhibitor in a Patient with Diabetes Mellitus,” <i>Intern Med</i>, 1997, 36:77.</p>\n<p>4. Rave K, Flesch S, Kuhn-Velten WN, et al, “Enhancement of Blood Glucose Lowering Effect of a Sulfonylurea When Coadministered with an Ace Inhibitor: Results of a Glucose-Clamp Study,” <i>Diabetes Metab Res Rev</i>, 2005, 21:459-64.</p>\n<p>5. Moore N, Kreft-Jais C, Haramburu F, et al, “Reports of Hypoglycaemia Associated with the Use of Ace Inhibitors and Other Drugs: A Case/Non-Case Study in the French Pharmacovigilance System Database,” <i>Br J Clin Pharmacol</i>, 1997, 44:513-8.</p>\n<p>6. Morris AD, Boyle DI, McMahon AD, et al, “Ace Inhibitor Use Is Associated with Hospitalization for Severe Hypoglycemia in Patients with Diabetes. Darts/Memo Collaboration. Diabetes Audit and Research in Tayside, Scotland. Medicines Monitoring Unit,” <i>Diabetes Care</i>, 1997, 20:1363-7.</p>\n<p>7. Herings RM, de Boer A, Stricker BH, et al, “Hypoglycaemia Associated with Use of Inhibitors of Angiotensin Converting Enzyme,” <i>Lancet</i>, 1995, 345:1195-8.</p>\n<p>8. Pedersen-Bjergaard U, Agerholm-Larsen B, Pramming S, et al, “Activity of Angiotensin-Converting Enzyme and Risk of Severe Hypoglycaemia in Type 1 Diabetes Mellitus,” <i>Lancet</i>, 2001, 357:1248-53.</p>\n<p>9. Pedersen-Bjergaard U, Agerholm-Larsen B, Pramming S, et al, “Prediction of Severe Hypoglycaemia by Angiotensin-Converting Enzyme Activity and Genotype in Type 1 Diabetes,” <i>Diabetologia</i>, 2003, 46:89-96.</p>\n<p>10. Oltmanns KM, Deininger E, Wellhoener P, et al, “Influence of Captopril on Symptomatic and Hormonal Responses to Hypoglycaemia in Humans,” <i>Br J Clin Pharmacol</i>, 2003, 55:347-53.</p>\n<p>11. Akram K, Pedersen-Bjergaard U, Carstensen B, et al, “Frequency and Risk Factors of Severe Hypoglycaemia in Insulin-Treated Type 2 Diabetes: A Cross-Sectional Survey,” <i>Diabet Med</i>, 2006, 23:750-6.</p>\n<p>12. Shorr RI, Ray WA, Daugherty JR, et al, “Antihypertensives and the Risk of Serious Hypoglycemia in Older Persons Using Insulin or Sulfonylureas,” <i>JAMA</i>, 1997, 278:40-3.</p>\n<p>13. Thamer M, Ray NF, Taylor T, “Association between Antihypertensive Drug Use and Hypoglycemia: A Case-Control Study of Diabetic Users of Insulin or Sulfonylureas,” <i>Clin Ther</i>, 1999, 21:1387-400.</p>\n<p>14. Ferriere M, Lachkar H, Richard JL, et al, “Captopril and Insulin Sensitivity,” <i>Ann Intern Med</i>, 1985, 102(1):134-5.</p>\n<p>15. McMurray J, Fraser DM, “Captopril, Enalapril, and Blood Glucose,” <i>Lancet</i>, 1986, 1(8488):1035.</p>\n<p>16. Tikellis C, Cooper ME, Thomas MC, “Role of the Renin-Angiotensin System in the Endocrine Pancreas: Implications for the Development of Diabetes,” <i>Int J Biochem Cell Biol</i>, 2006, 38:737-51.</p>\n<p>17. Glorioso N, Dessi-Fulgheri P, Alagna S, et al, “Angiotensin Converting Enzyme Inhibition Reduces ACTH Release Due to Hypoglycaemia,” <i>Clin Exp Hypertens A</i>, 1987, 9(2-3):665-70.</p>\n<p>18. Dessi-Fulgheri P, Alagna S, Madeddu P, et al, “Blunted Adrenocorticotrophic Hormone Release During Captopril Treatment,” <i>J Hypertens Suppl</i>, 1985, 3(2):S125-7.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9091":"<p><b>Title</b> Ciprofloxacin (Systemic) / Spironolactone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Spironolactone may enhance the arrhythmogenic effect of Ciprofloxacin (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use caution when considering the systemic use of ciprofloxacin in a patient who is receiving spironolactone. Consider monitoring patients closely for development of QT prolongation and/or new arryhthmias, particularly among older patients and those with other risk factors for the development of new arrhythmias.</p> \n<p><b>Discussion</b> A population-based retrospective study in patients age 66 and older who were receiving spironolactone and died of sudden death within 14 days of receiving a prescription for various antibiotics showed that concomitant administration of spironolactone with ciprofloxacin was associated with increased odds of sudden death when compared with amoxicillin [adjusted OR=1.6 (95% CI: 1.02 to 2.4)].<sup>1</sup> An additional sensitivity analysis, for which individuals were matched by disease risk index, resulted in a loss of statistical significance but only slightly lessened increase in odds [adjusted OR=1.4 (95% CI: 0.7 to 2.7)]. In a similar study by the same group, concurrent use of ciprofloxacin with angiotensin converting enzyme inhibitors or angiotensin receptor blockers was associated with an increased odds of sudden death when compared with amoxicillin [adjusted OR=1.3 (95% CI: 1.03 to 1.6)].<sup>2</sup><br><br>The mechanism for this purported interaction is uncertain, but it has been suggested that the combination of ciprofloxacin, which has been associated with prolongation of the QT interval and possible proarrhythmic effects, with a drug capable of causing hyperkalemia (e.g., spironolactone, other drugs acting on the renin-angiotensin-aldosterone system, etc.) may further increase the risk for dangerous proarrhythmic effects.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Antoniou T, Hollands S, Macdonald EM, et al. Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. <i>CMAJ</i>. 2015; Feb 2 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25646289\">[PubMed 25646289]</a></p>\n<p>2. Fralick M, Macdonald EM, Gomes T, et al. Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. <i>BMJ</i>. 2014;349:g6196. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25359996\">[PubMed 25359996]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9094":"<p><b>Title</b> Budesonide (Topical) / CYP3A4 Inhibitors (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: US prescribing information recommends avoiding the use of topical (rectal) budesonide and strong CYP3A4 inhibitors. Canadian product labeling warns of increased budesonide exposure with concomitant use but does not recommend avoidance of the combination.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Topical). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> US prescribing information recommends avoidance of the combination of topical (rectal) budesonide and strong CYP3A4 inhibitors. Canadian product labeling does not recommend avoidance of this combination, but does warn that increased budesonide exposure may occur. Monitor for excessive glucocorticoid effects if these agents are used concomitantly.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Although specific studies with rectally administered (topical) budesonide and strong CYP3A4 inhibitors are not available, the US prescribing information for rectal budesonide recommends avoiding use with CYP3A4 inhibitors based on interaction data with orally administered budesonide that showed an 8-fold increase in budesonide AUC with concurrent use of the strong CYP3A4 inhibitor ketoconazole.<sup>1</sup> Canadian product labeling warns that CYP3A4 inhibitors have the potential to increase budesonide systemic exposure but it does not recommend avoiding their use.<sup>2</sup><br><br>The average AUC and maximum serum concentration (Cmax) of budesonide were increased an average of 4.2- and 1.6-fold, respectively, when orally inhaled budesonide (1000 mcg) was administered with the strong CYP3A4 inhibitor itraconazole (200 mg/day x 5 days) in a study of 10 healthy volunteers.<sup>3</sup> The average elimination half-life of budesonide was increased from 1.6 to 6.2 hours with concurrent itraconazole, and the average plasma cortisol concentration was decreased by 43%, demonstrating the clinical significance of the increased budesonide concentrations. Case reports also describe patients treated with orally inhaled or oral budesonide who developed Cushing syndrome with concurrent use of the strong CYP3A4 inhibitors itraconazole,<sup>4</sup> ritonavir,<sup>5</sup> and atazanavir/ritonavir.<sup>6</sup><br><br>The likely mechanism of this interaction is inhibition of the CYP3A4 metabolism of budesonide, which is a CYP3A substrate, by strong CYP3A4 inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Uceris</i> (budesonide) [prescribing information]. Raleigh, NC: Salix Pharmaceuticals Inc; October 2014.</p>\n<p>2. <i>Entocort Enema</i> (budesonide) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; March 2009.</p>\n<p>3. Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT. Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole. <i>Clin Pharmacol Ther</i>. 2002;72(4):362-369. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12386638\">[PubMed 12386638]</a></p>\n<p>4. Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN. Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole. <i>Ann Pharmacother</i>. 2004;38(1):46-49. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14742792\">[PubMed 14742792]</a></p>\n<p>5. Kedem E, Shahar E, Hassoun G, Pollack S. Iatrogenic Cushing's syndrome due to coadministration of ritonavir and inhaled budesonide in an asthmatic human immunodeficiency virus infected patient. <i>J Asthma</i>. 2010;47(7):830-831. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20653496\">[PubMed 20653496]</a></p>\n<p>6. Frankel JK, Packer CD. Cushing's syndrome due to antiretroviral-budesonide interaction. <i>Ann Pharmacother</i>. 2011;45(6):823-824. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21558486\">[PubMed 21558486]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9095":"<p><b>Title</b> Budesonide (Topical) / CYP3A4 Inhibitors (Moderate)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: US prescribing information recommends avoiding the use of topical (rectal) budesonide and CYP3A4 inhibitors. Canadian product labeling warns of increased budesonide exposure with concomitant use but does not recommend avoidance of the combination.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Topical). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> US prescribing information recommends avoidance of the combination of topical (rectal) budesonide and any CYP3A4 inhibitors. Canadian product labeling does not recommend avoidance of this combination, but does warn that increased budesonide exposure may occur. Monitor for excessive glucocorticoid effects if these agents are used concomitantly.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> Although specific studies with rectally administered (topical) budesonide and moderate CYP3A4 inhibitors are not available, the US prescribing information for rectal budesonide recommends avoiding use with CYP3A4 inhibitors based on interaction data with orally administered budesonide that showed an 8-fold increase in budesonide AUC with concurrent use of the strong CYP3A4 inhibitor ketoconazole.<sup>1</sup> Canadian product labeling warns that CYP3A4 inhibitors have the potential to increase budesonide systemic exposure but it does not recommend avoiding their use.<sup>2</sup><br><br>The likely mechanism of this interaction is inhibition of the CYP3A4 metabolism of budesonide, which is a CYP3A substrate, by moderate CYP3A4 inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Uceris</i> (budesonide) [prescribing information]. Raleigh, NC: Salix Pharmaceuticals Inc; October 2014.</p>\n<p>2. <i>Entocort Enema</i> (budesonide) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; March 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9096":"<p><b>Title</b> Metoclopramide / Rivastigmine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Rivastigmine may enhance the adverse/toxic effect of Metoclopramide. Specifically, the risk of extrapyramidal adverse reactions may be increased with this combination. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of rivastigmine and metoclopramide because the risk of extrapyramidal adverse effects may be increased.</p> \n<p><b>Discussion</b> US prescribing information for rivastigmine recommends to avoid the combination of metoclopramide and rivastigmine due to the risk of additive extrapyramidal adverse reactions.<sup>1,2</sup><br><br>Cholinergic medications, such as rivastigmine, may exacerbate or induce extrapyramidal symptoms; worsening of parkinsonian symptoms was observed in patients with dementia<br>associated with Parkinson disease who were treated with rivastigmine.<sup>1,2</sup> Metoclopramide may increase the risk of extrapyramidal adverse effects through its anti-dopaminergic action.<sup>3</sup> The combination may result in an additive risk of developing extrapyramidal adverse reactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Exelon</i> (rivastigmine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2015.</p>\n<p>2. <i>Exelon Patch</i> (rivastigmine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2015.</p>\n<p>3. <i>Reglan</i> (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; August 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9097":"<p><b>Title</b> Beta-Blockers / Rivastigmine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Rivastigmine may enhance the bradycardic effect of Beta-Blockers. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to the risk of additive bradycardic effects, including syncope, the concomitant use of rivastigmine and beta-blockers is not recommended.</p>\n<div>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol, Arotinolol, Atenolol, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Esmolol, Labetalol, Levobunolol, Metipranolol, Metoprolol, Nadolol, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)</p>\n</div> \n<p><b>Discussion</b> One case report describes a 65-year-old woman who experienced syncope, episodes of bradycardia (heart rate less than 40 bpm), and sinus pauses greater than 2 seconds in duration after initiating the combination of rivastigmine (3 mg twice daily) and atenolol (25 mg daily).<sup>1</sup> She continued to have cardiac disturbances 14 hours after atenolol discontinuation and her cardiac rhythm stabilized only after rivastigmine was stopped.<sup>1</sup> <br><br>A retrospective cohort study from healthcare databases in Ontario, Canada found that after adjustment for numerous factors known to influence bradycardia and syncope risk (eg, age, sex, negative chronotropic drug use, cardiac conduction disorders), the use of acetylcholinesterase inhibitors (rivastigmine, galantamine, or donepezil) increased the risk of hospitalization for syncope, bradycardia, hip fracture, and need for permanent pacemaker implantation.<sup>2</sup> A case report also describes a 67-year-old woman who experienced complete heart block after initiation of rivastigmine without the use of any other medications known to slow heart rate.<sup>3</sup><br><br>Prescribing information for rivastigmine recommends against the use of beta-blockers in patients taking rivastigmine because of the risk of additive bradycardic events, including syncope.<sup>4,5</sup> Both agents are capable of lowering heart rate and their effects may be additive.<br><br>The mechanism of this potential interaction is that the acetylcholinesterase inhibitor rivastigmine lowers heart rate by increasing cholinergic tone and beta-blockers lower heart rate by blocking the actions of catecholamines at beta 1 receptors in the heart.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Paulison B, Leos CL. Potential cardiotoxic reaction involving rivastigmine and beta-blockers: a case report and review of the literature. <i>Cardiovasc Toxicol</i>. 2010;10(4):306-310. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20865460\">[PubMed 20865460]</a></p>\n<p>2. Gill SS, Anderson GM, Fischer HD, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. <i>Arch Intern Med</i> 2009;169(9):867-873. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19433698\">[PubMed 19433698]</a></p>\n<p>3. Kayrak M, Yazici M, Ayhan SS, Koc F, Ulgen MS. Complete atrioventricular block associated with rivastigmine therapy. <i>Am J Health Syst Pharm</i>. 2008;65(11):1051-1053. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18499878\">[PubMed 18499878]</a></p>\n<p>4. <i>Exelon</i> (rivastigmine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2015.</p>\n<p>5. <i>Exelon Patch</i> (rivastigmine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9098":"<p><b>Title</b> Palbociclib / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Palbociclib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of strong CYP3A4 inhibitors with palbociclib when possible. If the use of a strong CYP3A4 inhibitor cannot be avoided, decrease the palbociclib dose to 75 mg/day. Following discontinuation of the CYP3A4 inhibitor, consider an increase to the pre-interaction palbociclib dose after a period of 3 to 5 times the strong CYP3A4 inhibitor's half-life has passed.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The palbociclib AUC and maximum serum concentration were an average of 87% and 34% higher, respectively, with concurrent use of the strong CYP3A4 inhibitor itraconazole according to a study in which 12 healthy volunteers received a single dose of palbociclib (125 mg) together with itraconazole (200 mg/day).<sup>1</sup> Based on these findings, the palbociclib prescribing information recommends avoiding concurrent use of strong CYP3A4 inhibitors with palbociclib when possible.<sup>1</sup><br><br>Palbociclib appears primarily dependent on CYP3A4 and SULT2A1 for its metabolism,<sup>1</sup> making inhibition of CYP3A4 the likely mechanism for this interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Ibrance</i> (palbociclib) [prescribing information]. New York, NY: Pfizer Inc; February 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","9099":"<p><b>Title</b> Palbociclib / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Palbociclib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent consumption of grapefruit or grapefruit juice with palbociclib.</p> \n<p><b>Discussion</b> Data specific to the combined use of grapefruit juice and palbociclib are not available, but the palbociclib prescribing information recommends avoiding concurrent use due to the potential for grapefruit juice to inhibit CYP3A4.<sup>1</sup> The palbociclib AUC and maximum serum concentration were an average of 87% and 34% higher, respectively, with concurrent use of the strong CYP3A4 inhibitor itraconazole according to a study in which 12 healthy volunteers received a single dose of palbociclib (125 mg) together with itraconazole (200 mg/day).<sup>1</sup><br><br>Palbociclib appears primarily dependent on CYP3A4 and SULT2A1 for its metabolism,<sup>1</sup> making inhibition of CYP3A4 the likely mechanism for this potential interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Ibrance</i> (palbociclib) [prescribing information]. New York, NY: Pfizer Inc; February 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}